WO2004039817A1 - Cardiolipin molecules and method of synthesis - Google Patents

Cardiolipin molecules and method of synthesis Download PDF

Info

Publication number
WO2004039817A1
WO2004039817A1 PCT/US2003/027806 US0327806W WO2004039817A1 WO 2004039817 A1 WO2004039817 A1 WO 2004039817A1 US 0327806 W US0327806 W US 0327806W WO 2004039817 A1 WO2004039817 A1 WO 2004039817A1
Authority
WO
WIPO (PCT)
Prior art keywords
cardiolipin
composition
acid
liposome
mmol
Prior art date
Application number
PCT/US2003/027806
Other languages
French (fr)
Other versions
WO2004039817A9 (en
Inventor
Moghis U. Ahmad
Murali K. Ukkalam
Imran Ahmad
Original Assignee
Neopharm, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/013917 external-priority patent/WO2004062569A2/en
Priority claimed from PCT/US2003/016412 external-priority patent/WO2003099830A2/en
Application filed by Neopharm, Inc. filed Critical Neopharm, Inc.
Priority to JP2005501873A priority Critical patent/JP2006510733A/en
Priority to EA200500659A priority patent/EA200500659A1/en
Priority to CA002502285A priority patent/CA2502285A1/en
Priority to AU2003268478A priority patent/AU2003268478A1/en
Priority to EP03749443A priority patent/EP1556392A1/en
Priority to CA002501990A priority patent/CA2501990A1/en
Priority to EA200500661A priority patent/EA200500661A1/en
Priority to AU2003277445A priority patent/AU2003277445A1/en
Priority to JP2005501473A priority patent/JP2006503112A/en
Priority to EP03809159A priority patent/EP1558562A1/en
Priority to PCT/US2003/033099 priority patent/WO2004035523A1/en
Publication of WO2004039817A1 publication Critical patent/WO2004039817A1/en
Publication of WO2004039817A9 publication Critical patent/WO2004039817A9/en
Priority to US11/105,970 priority patent/US20050266068A1/en
Priority to HK05112200.6A priority patent/HK1080087A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Definitions

  • This invention pertains to novel synthetic methods for preparing cardiolipin analogs/variants, and compositions containing them.
  • the invention also pertains to liposome formulations or complexes or emulsions containing active agents or drugs and their use in the treatment of diseases in humans and animals.
  • Liposomal formulations have the capacity to increase the solubility of hydrophobic drugs in aqueous solution. They often reduce the side effects associated with drug therapy and they provide flexible tools for developing new formulations of active agents.
  • Liposomes are commonly prepared from natural phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, and phosphatidylinositol.
  • Anionic phospholipids such as phosphatidyl glycerol and cardiolipin, can be added to generate a net negative surface charge that provides for colloid stabilization. These components are often purified from natural sources and in some cases they can be chemically synthesized.
  • the nature and density of the surface charge of liposomes influences stability, kinetics, biodistribution, and interaction with, and uptake by target cells.
  • Liposome surface charge also influences the tendency for liposomes to aggregate, which makes liposomes difficult to work with and affects uptake by target cells.
  • liposomes with a neutral surface charge have the highest tendency to aggregate, but are less likely to be cleared by cells of the reticuloendothelial system (RES) after systemic administration.
  • RES reticuloendothelial system
  • Negatively charged liposomes exhibit reduced aggregation and increased stability, but exhibit non-specific cellular uptake in vivo.
  • a small amount of negatively charged lipids may stabilize neutral liposomes against an aggregation-dependent uptake mechanism (see, e.g., Drummond et al., Pharm. Rev., 51, 691-743 (1999)).
  • Cardiolipin also known as diphosphatidyl glycerol constitutes a class of complex anionic phospholipids that is typically purified from cell membranes of tissues associated with high metabolic activity, including the mitochondria of heart and skeletal muscles. The negative surface charge of cardiolipin, therefore, stabilizes liposomes against aggregation-dependent uptake, as discussed above.
  • cardiolipin contains up to 90% of linoleic acid (18:2).
  • Yeast cardiolipin differs in having more oleic (18:1) and palmitoleic (16:1) fatty acids, while the bacterial lipid contains saturated and monoenoic fatty acids with 14 to 18 carbons.
  • cardiolipin having shortchain fatty acids are unknown till now.
  • cardiolipin fatty acid chains i.e., saturated or unsaturated
  • Methods for synthesizing cardiolipin comprising short fatty acid chains (“short chain cardiolipin”) have not yet been described.
  • Cardiolipin has also been generated via a reaction between the silver salt of diacylglycerophosphoric acid benzyl ester with 1,3-diiodopropanol benzyl ether or 1,3-diiodopropanol t-butyl ether (see, e.g., De Haas et al., Biochim. Biophys.
  • Phosphate triesters and phosphoramidite esters have been used extensively in nucleic acid synthesis to form phosphate linkages, and to a lesser extent in phospholipid synthesis (see, e.g., Browne et al., J. Chem. Soc. Perkin Trans, 1, 653-657 (2000)). In this respect, Browne et al., supra, describes the preparation of phospholipid analogs, particularly phosphorylcholine analogs, using phosphoramidite methodologies.
  • the phosphatidylinositols PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 , and derivatives thereof, have been prepared using a variety of phosphoramidite reagents, including N, N- diisopropylphosphoramidite (see, e.g., Watanabe et al., Tetrahedron Lett. 35, 123-124 (1994)), difluorenyl phosphoramidite (see, e.g., Watanabe et al., Tetrahedron Lett.
  • phosphotriester analogs of PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 have been prepared utilizing the phosphoramidite reagent 2-cyano-ethyl N, N, N, N- tetraisopropylphosphorodiamidite (see, e.g., Gu et al, J. Org. Chem, 61, 8642-8647 (1996)).
  • Chem, 64, 648-651 (1999) describe the synthesis of phosphatidyl glycerol from 2,5-diben2yl-D-mannitol utilizing methyl tetraisopropylphosphorodiamidite as a phosphorylating agent.
  • phosphate triesters and phosphoramidite esters in preparing phospholipids such as cardiolipin, particularly cardiolipin species having varying fatty acid chain lengths, however, is not well established.
  • the invention provides novel synthetic methodologies for preparing cardiolipin having varying fatty acids and/or alkyl chains with varying length and saturation/unsaturation.
  • the methods comprises of (a) reacting an optically pure 1,2-O- diacyl-OT-glycerol or l,2-O-dialkyl-jn-glycerol with one or more phosphoramidite reagent(s) or one or more phosphate triester(s), (b) coupling the product of (a) with a 2- protected glycerol, wherein a protected cardiolipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared.
  • the invention also provides a method for preparing cardiolipin having varying fatty acid chain lengths comprising (a) reacting a 2-O-protected glycerol with one or more phosphoramidite reagents, wherein a phosphorylating agent is produced, (b) reacting the phosphorylating agent with an optically pure 1,2-O-diacyl-sr ⁇ -glycerol or l,2-O-dialkyl-,sn-glycerol, wherein a protected cardiolipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared.
  • the cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays.
  • Figure 1 depicts the general structure of cardiolipin.
  • Figure 2 depicts one scheme for synthesizing cardiolipin.
  • Figure 3 depicts an alternative synthetic scheme for cardiolipin.
  • Figure 4 depicts an alternative synthetic scheme for cardiolipin.
  • Figure 5 depicts an alternative synthetic scheme for cardiolipin.
  • Figure 6 depicts an alternative synthetic scheme for cardiolipin ether analogs.
  • Figure 7 depicts an alternative synthetic scheme for cardiolipin ether analogs.
  • the present invention describes methods for the synthesis of cardiolipin variants and analogs having the general formulas I, II, and III, as well as compositions containing such variants and analogs.
  • Yj. andY 2 are the same or different and are -O-C(O)-, -O-, -S-, -NH-C(O)- or the like.
  • R t and R 2 are the same or different and are H, saturated and/or unsaturated alkyl group, preferably a C 2 to C 34 saturated and/or unsaturated alkyl group.
  • R 4 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, a peptide, dipeptide, polypeptide, protein, carbohydrate (such as glucose, mannose, galactose, polysaccharide and the like), lieterocyclic, nucleoside, polynucleotide and the like.
  • R 5 is a linker, which may (or may not be) added in the molecule depending on the need and applications.
  • R 5 can comprise alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, polyalkyloxy (such as pegylated ether of containing from about 1 to 500 alkyloxymers (and can have at least about 10 alkyloxy mers, such as at least about 50 alkyloxy mers or at least about 100 alkyloxy mers, such as at least about 200 alkyloxy mers or at least about 300 alkyloxy mers or at least about 400 alkyloxy mers), substituted polyalkyloxy and the like), a peptide, dipeptide, polypeptide, protein, carbohydrate such as glucose, mannose, galactose, polysaccharides and the like.
  • X is hydrogen or a non-toxic cation, preferably ammonium, sodium, potassium, calcium, barium ion and the like.
  • alkyl encompasses saturated or unsaturated straight-chain and branched-chain hydrocarbon moieties.
  • substituted alkyl comprises alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy (of a lower alkyl group), mercapto (of a lower alkyl group), cycloalkyl, substituted cycloalkyl, halogen, cyano, nitro, amino, a ido, imino, thio, -C(O)H, acyl, oxyacyl, carboxyl, and the like.
  • Y ⁇ and Y 2 in Formula III are -O-C(O)- or -O-.
  • R 3 is most preferably is CH 2 .
  • Ri and R 2 are the same and are a C 2 to C 13 saturated and/or unsaturated alkyl group, more preferably between 4 and 14 carbon atoms (such as between about 6 and 12 carbon atoms).
  • X is most preferably is hydrogen or ammonium ion. In the absence of linker (R 5 ), it gives the general structure of cardiolipin ( Figure 1).
  • the invention provides a method for preparing cardiolipin or an analogue thereof of Formulas I, II, or III, comprising reacting an alcohol of the formula VIII with one or more phosphoramide reagents and 2-O-protected glycerol or 2-O-subsituted glycerol VI in the presence of an acid catalyst.
  • Y in formula VI is a hydroxyl protecting group, preferably alkyl group or the like, or a silyl protecting group.
  • Ri, R 2 , R 3 , Yi, and Y 2 can be as indicated above with respect to Formulas I, II, or ⁇ i.
  • the acid catalyst can be any suitable catalyst that can facilitate the reaction.
  • catalysts examples include 4,5-dichloroimidazole, lH-tetrazole, 5-(4-nitrophenyl)-lH-tetrazole, 5-(3,5- dinitrophenyl)-lH-tetrazole, N-methylimidazolium triflate, and N-methylimidazolium perchlorate, 4,5-dicyanoimidazole, 5-ethylthio-lH-tetrazole, and 5-methylthio-lH-tetrazole.
  • Preferred catalysts are 4,5-dichloroimidazole orlH-tetrazole.
  • the coupling phosphoramidites can have formula IV or V:
  • the invention provides a method for preparing cardiolipin or an analogue thereof of formulas I, II, or III; comprising reacting 2-O protected glycerol with one or more phosphotriesters in the presence of pyridinium tribromide.
  • Preferred phosphotriesters can be produced by reacting an alcohol of formula VIII with phosphoramidite of general formula VII.
  • X in Formulas IV, V, or VII is a phosphate protecting group, preferably a benzyl group or 2-cyanoethyl or silyl group.
  • suitable protecting groups include alkyl phosphates including ethyl, cyclohexyl, t-butyl; 2-substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2-(methyldiphenylsilyl)ethyl, 2- (trimethylsily ⁇ )ethyl, 2-(triphenylsilyl)ethyl; haloethyl phosphates including 2,2,2- trichloroethyl, 2,2,2-tribromoethyl, 2,2,2-trifluoroethyl; benzyl phosphates including 4- chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates.
  • FIG. 2 & 3 A general sequence of reactions for the synthesis of compound of invention is illustrated in Figures 2 & 3.
  • the present invention provides a method for preparing cardiolipin I having varying fatty acid chain lengths comprising (a) reacting an optically pure l,2-O-diacyl--f «-glycerol 2 with one or more phosphoramidite reagent(s)of the general formula IV (figure 2) or V (figure 3) (b) coupling the product of (a) 3 with a 2-O-protected glycerol VI in a chlorinated solvent (for example dichloromethane, chloroform or like) followed by oxidation with m-chloroperoxybenzoic acid (m-CPBA) results in the production of a protected cardiolipin 4. Thereafter, deprotecting the protected cardiolipin followed by conversion to ammonium salt will result in the production of cardiolipin 1 (ammonium salt).
  • a chlorinated solvent for example dichloromethane, chloroform
  • any suitable phosphoramidite reagent or methodology may be used, such as is described in, for example Browne et al., supra.
  • suitable phosphoramidite reagents include (benzyloxyXN N-diisopropylamino)chlorophosphine (see, e.g., Prestwich et al. J. Am. Chem. Soc. 1991, 113, 1822-1825), benzyloxybis (diisopropylamino) phosphine (see, e.g., Dreef et al. Tetrahedron Lett.
  • the optically pure l,2-O-diacyl-,s72-glyeerol 2 can be phosphorylated using phosphoramidite VII to yield phosphite triesters 5 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy 1,3-propanediol or 2- levulinoyl-1.
  • 2-O-protected glycerol VI such as, for example, benzyloxy 1,3-propanediol or 2- levulinoyl-1.
  • 3-propanediol using pyridinium perbromide and phosphoniurn salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin 4.
  • the preferred coupling reagent in this context of synthetic methods is dibenzyl diisopropylphosphoramidite.
  • the inventive method comprises (a) reacting a 2-O-protected glycerol VI with one or more phosphoramidite reagents IV or V, wherein a phosphorylating agent 6 is produced, (b) reacting the phosphorylating agent 6 with an optically pure l,2-O-diacyl-s «-glycerol 2 followed by oxidation with m-CPBA, wherein a protected cardiolipin 4 is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared.
  • Suitable phosphoramidite reagents and 2-O-protected glycerols for use in this aspect of the inventive method are described above.
  • FIG. 6 Another embodiment of the present invention, represented in Figure 6 leads to ether analogs of cardiolipin, wherein the acyl groups are replaced by alkyl chain. Accordingly (a) 1,2-O-dialkyl- ⁇ -glycerol 7 is treated with phosphoramidites IV or V wherein a phosphorylating agent 8 is produced, (b) reacting the phosphorylating agent with a 2-O-protected glycerol VI followed by oxidation, wherein a protected cardiolipin 9 is produced, and (c) deprotecting the protected cardiolipin, such that the ether analog of cardiolipin 10 is produced. [0030] Another embodiment of the present invention is depicted in Figure 7.
  • the optically pure 1,2-O-dialkyl-OT-glycerol 7 can be phosphorylated using phosphoramidite VII to yield phosphite triesters 11 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy 1,3-propanediol or 2- levulinoyl-1, 3-propanediol using pyridinium perbromide and phosphonium salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin ether analog 9.
  • the preferred coupling reagent in this context of synthetic methods is dibenzyl diisopropylphosphoramidite.
  • the invention described above is an elegant and efficient method of synthesizing cardiolipin.
  • the routes are short and proceed in good overall yield.
  • the deprotection can be accomplished by a method depending on the protecting group.
  • a benzyl group can be removed by catalytic hydrogenolysis or by treatment with Nal, 2-cyanoethyl and fluorenylmethyl groups by treatment with a tertiary base such as triethylamine
  • a silyl group can be deprotected with fluoride ion or acidic medium, a levulinoyl group by hydrazinolysis.
  • phosphoramidites and phosphate esters can be prepared using a variety of acid catalysts, including 4,5-dichloroimidazole (see, e.g., Browne et al.), 5-(4-nitrophenyl)-lH- tetrazole, 5-(3,5-dinitrophenyl)-lH-tetrazole, N-methylimidazolium triflate, and N- methylimidazolium perchlorate (see, e.g., Moriguchi et al.).
  • tert- butylhydroperoxide can be used as an alternative oxidant.
  • the described methods can be further modified in any suitable manner known in the art.
  • the inventive method can be used to prepare cardiolipin species comprising fatty acid /alkyl chains of varying length and saturation/unsaturation.
  • the general structure of a phospholipid fatty acid comprises a hydrocarbon chain and a carboxylic acid group.
  • the length of the fatty acid hydrocarbon chain ranges from about 2 to about 34 carbon atoms and can be saturated or unsaturated.
  • the carbon chain is more typically between about 12 and about 24 carbon atoms.
  • the length of the fatty acid hydrocarbon is less than about 24 carbon acids, such as less than about 24 carbon atoms, or even less than about 20 carbon atoms.
  • the invention also provides a cardiolipin or cardiolipin analogue prepared in accordance with the inventive method.
  • the cardiolipin prepared by the inventive method comprises a short fatty acid chain (i.e., a "short chain cardiolipin"), and the invention provides a short chain cardiolipin.
  • a short fatty acid chain comprises between about 2 and between about 14 carbon atoms, and can have between about 4 (or about 6) and about 12 carbon atoms, such as between about 8 and about 10 carbon atoms.
  • the cardiolipin produced by the inventive method can comprise a long chain fatty acid chain (i.e., a "long chain cardiolipin").
  • a long fatty acid chain comprises between about 14 and about 34 carbon atoms, such as between about 14 (or between about 20) and about 24 carbon atoms.
  • the inventive method is not limited to the production of short or long chain cardiolipin species exclusively. Indeed, a cardiolipin containing fatty acid alkyl chains of intermediate length can also be prepared by the inventive method.
  • Phospholipid fatty acids typically are classified by the number of double and/or triple bonds in the hydrocarbon chain (i.e., unsaturation).
  • a saturated fatty acid does not contain any double or triple bonds, and each carbon in the chain is bound to the maximum number of hydrogen atoms.
  • the degree of unsaturation of a fatty acid depends on the number of double or triple bonds present in the hydrocarbon chain. In this respect, a mon ⁇ unsaturated fatty acid contains one double bond, whereas a polyunsaturated fatty acid contains two or more double bonds (see, e.g., Oxford Dictionary of Biochemistry and Molecular Biology, rev. ed., A.D. Smith (ed.), Oxford University Press (2000), and Molecular Biology of the Cell, 3 rd ed., B.A. Alberts (ed.), Garland Publishing, New York (1994)).
  • the fatty acid chains of the cardiolipin are prepared by the inventive method, whether short or long, also can be saturated or unsaturated.
  • the described methods can be used to prepare a variety of novel cardiolipin molecules.
  • the methods can be used to prepare cardiolipin variants in pure form containing short or long fatty acid side chains.
  • Preferred fatty acids range from carbon chain lengths of about C 2 to C 3 , preferably between about C and about C 2 , and include tetranoic acid (C 4: o), pentanoic acid (C 5 :o), hexanoic acid (C ⁇ -.o heptanoic acid (C 7: o), octanoic acid (C 8: o), nonanoic acid (C 9: o), decanoic acid (C ⁇ o : o), undecanoic acid (C 11: o), dodecanoic acid (C ⁇ 2: o), tridecanoic acid (C 13: o), tetradecanoic (myristic) acid (C ⁇ : o), pentadecanoic acid (Ci5 : o), pen
  • the alkyl chain will also range from C 2 to C 3 preferably between about C and about C 2 .
  • Other fatty acid chains also can be employed as Ri and or R 2 substituents. Examples of such include saturated fatty acids such as ethanoic (or acetic) acid, propanoic (or propionic) acid, butanoic (or butyric) acid, hexacosanoic (or cerotic) acid, octacosanoic (or montanic) acid, triacontanoic (or melissic) acid, dotriacontanoic (or lacceroic) acid, tetratriacontanoic (or gheddic) acid, pentatriacontanoic (or ceroplastic) acid, and the like; monoefhenoic unsaturated fatty acids such as trcms ⁇ -butenoic (or crotonic) acid, cis-2- butenoic (
  • 'hydroxyl protecting group' used herein the invention refers to the commonly used protecting groups disclosed by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999).
  • Such protecting groups include methyl ether, substituted methyl ethers including methoxymethyl, benzyloxymethyl, ⁇ -methoxybenzyloxymethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl ethers; substituted ethyl ethers like 1-ethoxyethyl, 1- methyl-1-benzyloxy ethyl, allyl, propargyl; benzyl and substituted benzyl ethers including p- methoxybenzyl, 3,4-dimethoxybenzyl, triphenylmethyl; silyl ethers including trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, diphenylmethylsilyl; esters including formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, benzoate, levuliny
  • 'phosphate protecting group' used herein the invention refers to the commonly used protecting groups described by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999).
  • Such protecting groups include alkyl phosphates including methyl, ethyl, cyclohexyl, t-butyl; 2- substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2- (methyldiphenylsilyl)ethyl, 2-(trimethylsilyl)ethyl, 2-(triphenylsilyl)ethyl; haloethyl phosphates including 2,2,2-trichloroethyl, 2,2,2-tiibromoethyl, 2,2,2-trifluoroethyl; benzyl phosphates including 4-chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates.
  • the cardiolipin molecules described herein and cardiolipins produced by the inventive method can be used in lipid formulations, such as liposomal compositions. Complexes, emulsions and other formulations including the inventive cardiolipin also are within the scope of the present invention.
  • Such formulations according to the present invention can be prepared by any suitable technique.
  • the invention provides a method for preparing a liposome or other lipid composition, comprising preparing a cardiolipin or cardiolipin analogue as described herein and including the cardiolipin or cardiolipin analogue in a lipid formulation, such as a liposome.
  • the invention also includes such lipid compositions including the inventive cardiolipin and/or cardiolipin analogues.
  • the liposomal composition, complex, emulsion and the like can include other lipids.
  • the composition can include one or more phosphatidylcholines, such as, for example, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof.
  • phosphatidylcholines such as, for example, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidyl
  • the composition can include one or more phosphatidylglycerols, such as dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, and mixtures thereof.
  • the composition can include one or more sterols, such as cholesterol, derivatives of cholesterol, coprostanol, cholestanol, cholestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.
  • the composition in addition to the cardiolipin or cardiolipin analogue, includes a phosphatidylcholine, a sterol, and a tocopherol (e.g., ⁇ -tocopherol).
  • the composition also can include stabilizers, absorption enhancers, antioxidants, phospholipids, biodegradable polymers and medicinally active agents among other ingredients.
  • it is preferable for the inventive composition, especially liposomal composition to include one or more targeting agents, such as carbohydrate or a protein or other ligand that binds to a specific substrate, for example, that recognize cellular receptors.
  • the composition also can include one or more active agents.
  • a single active agent can be included, or a mixture of active agents (e.g., two or more active agents) can be included within the composition.
  • Active agents can be present in any suitable manner in the composition. For example, they can be complexed with the cardiolipin or cardiolipin analogue in the composition. Additionally, or alternatively, one or more active agents can be entrapped within liposomes, when the composition is a liposomal composition.
  • Active agents which are compatible with the present invention include, for example, agents which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synaptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, the alimentary and excretory systems, the histamine system and the central nervous system.
  • Suitable agents may be selected from, for example, proteins, enzymes, hormones, nucleotides (including sense and antisense oligonucleotides (see, e.g., U.S.
  • Patent 6,126,965 polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids.
  • Active agents can be analgesics, anesthetics, anti-arrythmic agents, antibiotics, antiallergic agents, antifungal agents, anticancer agents, anticoagulants, antidepressants, antidiabetic agents, anti-epilepsy agents, anti-inflammatory corticosteroids, agents for treating Alzheimers or Parkinson's disease, antiulcer agents, anti-protozoal agents, anxiolytics, thyroids, anti-thyroids, antivirals, anoretics, bisphosphonates, cardiac inotropic agents, cardiovascular agents, corticosteroids, diuretics, dopaminergic agents, gastrointestinal agents, hemostatics, hypercholesterol agents, antihypertensive agents (e.g., dihydropyridines), antidepressants, and cox-2 inhibitors, immunosuppressive agents, anti- g
  • the therapeutic agents can be nephrotoxic, such as cyclosporins and amphotericin B, or cardiotoxic, such as amphotericin B and paclitaxel.
  • exemplary anticancer agents include melphalan, chlormethine, extramustinephosphate, uramustine, ifosfamide, mannomustine, trifosfamide, streptozotocin, mitobronitol, mitoxantrone (see., e.g., published international patent application WO 02/32400), methotrexate, fluorouracil, cytarabine, tegafur, idoxide, taxanes (e.g., taxol, paclitaxel, etc., see published international patent application WO 00/01366), daunomycin, daunorubicin, bleomycin, amphotericin, carboplatin, cisplatin, paclitaxel, BC ⁇ U, vinca alkaloids (e.
  • drugs which may be delivered according to the method include, prochlorperzine edisylate, ferrous sulfate, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzamphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, metliylphenidate hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethy
  • proteins and peptides which include, but are not limited to, bone morphogenic proteins, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, digestive hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatotropin, oxytocin, vasopressin, GRF, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, LHRH agonists and antagonists, leuprolide, interferons (e.g., consensus interferon, interferon ⁇ -2a, interferon cc-2b, ⁇ -, ⁇ -, or ⁇ - interferons), interleuldns, growth hormones such as human growth hormone and its derivatives such as methione-human
  • liposomes can have a net neutral, negative or positive charge.
  • positive liposomes can be formed from a solution containing phosphatidylcholine, cholesterol, cardiolipin and enough stearylamine to overcome the net negative charge of cardiolipin.
  • Negative liposomes can be formed from solutions containing phosphatidyl choline, cholesterol, and/or cardiolipin variants prepared by the methods described herein.
  • the liposomes of the present invention can be multi or unilamellar vesicles depending on the particular composition and procedure to make them.
  • Liposomes can be prepared to have substantially homogeneous sizes in a selected size range, such as about 1 micron or less, or about 500 nm or less, about 200nm or less, or about lOOnm or less.
  • One effective sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size; the pore size of the membrane will correspond roughly with the largest sizes of liposomes produced by extrusion through that membrane.
  • the liposomal (or other lipid) composition can be in any desired form.
  • the composition can be ready for administration to a patient.
  • the composition can be in dried or lyophilized form.
  • cryoprotectant include, for example, sugars such as tiehalose, maltose, lactose, sucrose, glucose, and dextran, with the most preferred sugars from a performance point of view being tiehalose and sucrose.
  • sugars such as tiehalose, maltose, lactose, sucrose, glucose, and dextran
  • Other more complicated sugars can also be used, such as, for example, aminoglycosides, including streptomycin and dihydrostreptomycin.
  • Any suitable method can be employed to form the liposomes.
  • lipophilic liposome-forming ingredients such as phosphatidylcholine, a cardiolipin prepared by the methods described above, cholesterol and ⁇ -tocopherol can be dissolved or dispersed in a suitable solvent or combination of solvents and dried.
  • suitable solvents include any non-polar or slightly polar solvent, such as t-butanol, ethanol, methanol, chloroform, or acetone that can be evaporated without leaving a pharmaceutically unacceptable residue. Drying can be by any suitable means such as by lyophilization. The dehydration is typically achieved under vacuum and can take place either with or without prior freezing of the liposome preparation.
  • Hydrophilic ingredients can be dissolved in polar solvents, including water.
  • the invention provides a method for retaining a drug in a liposome.
  • cardiolipin or cardiolipin analogue is prepared as described herein, and the cardiolipin or cardiolipin analogue and a drug or drugs (e.g., an active agent a mixture of active agents) is included within a liposome.
  • active agent(s) can be dissolved or dispersed in a suitable solvent and added to the liposome mixture prior to mixing.
  • hydrophilic active agents will be added directly to the polar solvent and hydrophobic active agents will be added to the nonpolar solvent used to dissolve the other ingredients but this is not required.
  • the active agent could be dissolved in a third solvent or solvent mix and added to the mixture of polar solvent with the lipid film prior to homogenizing the mixture.
  • Liposomes can be coated with a biodegradable polymers such as sucrose, epichlorohydrin, branched hydrophilic polymers of sucrose, polyethylene glycols, polyvinyl alcohols, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene oxide, polyoxyethylene, polyoxypropylene, cellulose acetate, sodium alginate, ⁇ , ⁇ - diefhylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene, polyvinyl pyrrolidone, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, and polyoxyethylene sorbitan esters.
  • a biodegradable polymers such as sucrose, epichlorohydrin, branched hydrophilic polymers of sucrose, polyethylene glycols, polyvinyl alcohols, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene oxide, polyoxyethylene, polyoxypropylene, cellulose a
  • Antioxidants can be included in the liposomal composition or other lipid composition. Suitable antioxidants include compounds such as ascorbic acid, tocopherol, and deteroxime mesylate.
  • Absorption enhancers can be included in the liposomal composition or other lipid composition. Suitable absorption enhancers include Na-salicylate-chenodeoxy cholate, Na deoxycholate, polyoxyethylene 9-lauryl ether, chenodeoxy cholate- deoxycholate and polyoxyethylene 9-lauryl ether, monoolein, Na tauro-24,25- dihydrofusidate, Na taurodeoxycholate, Na glycochenodeoxycholate, oleic acid, linoleic acid, linolenic acid.
  • inventive lipid (e.g., liposomal) composition also can include one or more pharmaceutically acceptably excipients.
  • pharmaceutically suitable excipients include solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds.
  • the invention also includes pharmaceutical preparations in dosage units.
  • the preparations are in the form of individual parts, for example vials, syringes, capsules, pills, suppositories, or ampoules, of which the content of the liposome formulation of active agent corresponds to a fraction or a multiple of an individual dose.
  • the dosage units can contain, for example, 1, 2, 3, or 4 individual doses, or 1/2, 1/3, or 1/4 of an individual dose.
  • An individual dose preferably contains the amount of active agent which is given in one administration and which usually corresponds to a whole, a half, a third, or a quarter of a daily dose.
  • Tablets, dragees, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays can be suitable pharmaceutical preparations.
  • Suppositories can contain, in addition to the liposomal active agent, suitable water-soluble or water-insoluble excipients. Suitable excipients are those in which the inventive liposomal active agent is sufficiently stable to allow for therapeutic use, for example polyethylene glycols, certain fats, and esters or mixtures of these substances.
  • Ointments, pastes, cream, and gels can also contain suitable excipients in which the liposomal active agent is stable.
  • the composition also can be formulated for injection (e.g., intravenously, interstitially, intratumorally, etc) by the inclusion of one or more excipients (e.g., buffered saline) suitable for injection.
  • the active agent or its pharmaceutical preparations can be administered intravenously, subcutaneously, locally, orally, parenterally, intraperitoneally, and/or rectally or by direct injection into tumors or sites in need of treatment by such methods as are known or developed.
  • Cardiolipin and cardiolipin-analog based formulations also can be administered topically, e.g., as a cream, skin ointment, dry skin softener, moisturizer, etc.
  • the invention provides for the use of the composition to prepare a medicament for the treatment of a disease. In this sense, the invention also provides a method for treating a human or animal disease.
  • the inventive composition is exposed to (administered to) a human or animal patient in need of such treatment.
  • the inventive method facilitates delivery of the active agent(s) to the patient.
  • the method can be used to administer one or more active agents. It is thought to be general for active agents that are stable in the presence of surfactants. Hydrophilic active agents are suitable and can be included in the interior of the liposomes such that the liposome bilayer creates a diffusion barrier preventing it from randomly diffusing throughout the body. Hydrophobic active agents are thought to be particularly well suited for use in the present method because they not only benefit by exhibiting reduced toxicity but they tend to be well solubilized in the lipid bilayer of liposomes.
  • Suitable diseases for treatment will depend on the selection of active agents, such as described herein. However a preferred disease is cancer, in which instance, at least one active agent incorporated into the composition is an anticancer agent.
  • Chemotherapeutic agents are well suited for such use. Liposome formulations containing chemotherapeutic agents may be injected directly into the tumor tissue for delivery of the chemotherapeutic agent directly to cancer cells. In some cases, particularly after resection of a tumor, the liposome formulation can be implanted directly into the resulting cavity or may be applied to the remaining tissue as a coating.
  • the method can be employed to treat diseases, disorders, or symptoms within patients even where the composition does not contain an active pharmaceutical agent other than cardiolipin.
  • the invention provides for the use of cardiolipin to prepare a medicament to combat or treat such diseases, disorders, or symptoms.
  • the invention further provides a method of treating such diseases, disorders, or symptoms within patients, and the effects of such diseases, disorders, or symptoms by administering to the patient a therapeutically effective amount of cardiolipin.
  • cardiolipin provides a beneficial antioxidant effect, which can alleviate the effects of many diseases, disorders, or symptoms.
  • conditions that can be treated in accordance with the method include, for example, age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders (e.g., acne, psoriasis, eczema, etc.).
  • the method also can be employed to combat the effects of aging.
  • the cardiolipin can be formulated as a liposomal or non- liposomal formulation (e.g., an emulsion, cream, etc.) as discussed herein and can include, in addition to cardiolipin, one or more pharmaceutically acceptable carriers.
  • the composition can be administered by any suitable route.
  • the composition can be administered dermally, intravenously, or by other desired route of administration.
  • the invention also is directed to methods of delivering active agents (or mixtures of active agents) to cells.
  • the methods can be carried out by preparing liposomes that include active agents and cardiolipin variants/analogs as synthesized by the above disclosed methods.
  • the liposomes are then delivered to a cell or cells, which can be in vitro or in vivo, as desired. In vivo administration can be achieved as described herein or as otherwise known to those of ordinary skill.
  • composition e.g., liposomes
  • delivery of the active agent(s) can be carried out by adding the composition (e.g., liposomes) to the cell culture medium, for example.
  • Ri, R 2 myristoyl (C 1 : o chain)
  • Ri, R2 myristoyl (C 14:0 chain)
  • the catalyst was filtered off over celite bed, treated with 4 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC1 3 , filtered through a 0.25 ⁇ filter and precipitated with acetone to give tetramyristoyl (Cj-j.-o) cardiolipin (1.75 g, 83%) as a white solid.
  • R l5 R 2 lauroyl (C ⁇ 2: o chain)
  • Method 1 A solution of 1 ,2-dilauroyl-- -glycerol (2.2 g, 4.82 mmol), benzyl N N-tetraisopropyl phosphoramidite (1.95 g, 5.78 mmol) and lH-tetrazole (12.84 mL of 0.45 M sol in acetonitrile, 5.78 mmol) in CH 2 C1 2 (25 mL) was stirred at room temperature under argon for 3 h.
  • Method 2 To a stirred solution of 1,2-Dilauroyl-r ⁇ -glycerol (5.0 g, 10.96 mmol) and tetrazole (29.2 mL of 0.45 M sol in acetonitrile, 13.15 mmol) in 40 mL anhydrous CH 2 CI 2 , dibenzyl diisopropyl phosphoramidite (4.54g, 13.15 mmol) was added and stirred at room temperature for 2 h.
  • Ri, R 2 lauroyl (C 12: o chain)
  • Ri, R2 lauroyl (C 12: o chain)
  • Ri, R 2 decanoyl ( oio chain)
  • Ri, R2 decanoyl (C ⁇ o chain)
  • Ri, R 2 decanoyl (C ⁇ o : o chain)
  • Ri, R2 octanoyl (C 8: o chain)
  • Ri, R2 octanoyl (C 8: o chain)
  • R l5 R 2 octanoyl (C 8: o chain)
  • l,2-Dioctanoyl-,s' «-glycerol from 5B (5.0 g, 14.53 mmol) and tetrazole (40.3 mL of 0.45 M sol in acetonitrile, 18.16 mmol) in 50 mL anhydrous CH 2 C1 2 dibenzyl diisopropyl phosphoramidite (6.26g, 18.16 mmol) was added and stirred at room temperature for 2 h.
  • Ri, R2 hexanoyl (C 6: o chain)
  • Ri, R2 oleoyl (C 18:1 chain)
  • R ls R 2 hexyl (C 6: o chain)
  • Example 10 This example demonstrates preparation of a cardiolipin-containing liposome composition of the invention.
  • Small unilamellar vesicles are formed by mixing 19.1 ⁇ mole of cardiolipin, produced according to the methods described herein, 96.2 ⁇ mol of phosphatidyl choline and 64.6 ⁇ mol of cholesterol. After thorough stirring, the mixture is evaporated to dryness in a 50 ml round-bottom flask using a rotary evaporator. The subsequent dried lipid film is resuspended in 10 ml sterile non-pyrogenic water. After a 30 minute swelling time, the resulting suspension is sonicated in a fixed temperature bath at 25 °C for 15 minutes. The preparation of liposomes is then lyophilized with tiehalose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides new synthetic routes for cardiolipin with different fatty acids and/or alkyl chains with varying chain length and also with or without unsaturation, particularly a short-chain cardiolipin. The methods comprise reacting a 1,2-O-sn-diacyl/1,2-O-sn-dialkyl glycerol or a 2-O-protected glycerol, with a phosphoramidite reagent or a phosphate triester to produce a protected cardiolipin, which is deprotected to prepare the short chain cardiolipin. The reaction schemes can be used to generate new variants of cardiolipin. The cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays. Liposomes can also include ligands for targeting a particular cell type or specific tissue.

Description

CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS
FIELD OF THE INVENTION
[0001] This invention pertains to novel synthetic methods for preparing cardiolipin analogs/variants, and compositions containing them. The invention also pertains to liposome formulations or complexes or emulsions containing active agents or drugs and their use in the treatment of diseases in humans and animals.
BACKGROUND OF THE INVENTION
[0002] Liposomal formulations have the capacity to increase the solubility of hydrophobic drugs in aqueous solution. They often reduce the side effects associated with drug therapy and they provide flexible tools for developing new formulations of active agents.
[0003] Liposomes are commonly prepared from natural phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, and phosphatidylinositol. Anionic phospholipids, such as phosphatidyl glycerol and cardiolipin, can be added to generate a net negative surface charge that provides for colloid stabilization. These components are often purified from natural sources and in some cases they can be chemically synthesized. [0004] The nature and density of the surface charge of liposomes influences stability, kinetics, biodistribution, and interaction with, and uptake by target cells. Liposome surface charge also influences the tendency for liposomes to aggregate, which makes liposomes difficult to work with and affects uptake by target cells. In this respect, liposomes with a neutral surface charge have the highest tendency to aggregate, but are less likely to be cleared by cells of the reticuloendothelial system (RES) after systemic administration. Negatively charged liposomes, on the other hand, exhibit reduced aggregation and increased stability, but exhibit non-specific cellular uptake in vivo. Thus, it has been suggested that a small amount of negatively charged lipids may stabilize neutral liposomes against an aggregation-dependent uptake mechanism (see, e.g., Drummond et al., Pharm. Rev., 51, 691-743 (1999)). [0005] Cardiolipin (also known as diphosphatidyl glycerol) constitutes a class of complex anionic phospholipids that is typically purified from cell membranes of tissues associated with high metabolic activity, including the mitochondria of heart and skeletal muscles. The negative surface charge of cardiolipin, therefore, stabilizes liposomes against aggregation-dependent uptake, as discussed above. In animal tissues and mitochondria, cardiolipin contains up to 90% of linoleic acid (18:2). Yeast cardiolipin differs in having more oleic (18:1) and palmitoleic (16:1) fatty acids, while the bacterial lipid contains saturated and monoenoic fatty acids with 14 to 18 carbons. However cardiolipin having shortchain fatty acids are unknown till now. The potential effects of the length and nature of cardiolipin fatty acid chains (i.e., saturated or unsaturated) on liposome aggregation have not been elucidated. [0006] Methods for synthesizing cardiolipin comprising short fatty acid chains ("short chain cardiolipin") have not yet been described. Generally, known methodologies for synthesizing cardiolipin are mainly divided in two groups: (a) coupling the primary hydroxyl groups of a 2-protected glycerol with l,2-diacyl-5«-glycerol using a phosphorylating agent and (b) condensation at both primary hydroxyl groups of a 2- protected glycerol with phosphatidic acid in the presence of 2,4,6- triisopropylbenzenesulfonylchloride (TPS) or pyridine (see, e.g., Ramirez et al., Synthesis, 11, 769-710 (1976), Duralski et al., Tetrahedron Lett. 39, 1607-1610 (1998), Saunders and Schwarz, J. Am. Chem. Soc. 88, 3844-3847 (1966), Mishina et al., Bioorg. Khim. 11, 992- 994 (1985), and Stepanov et al., Zh. Org, Khim. 20, 985-988 (1984)). Cardiolipin has also been generated via a reaction between the silver salt of diacylglycerophosphoric acid benzyl ester with 1,3-diiodopropanol benzyl ether or 1,3-diiodopropanol t-butyl ether (see, e.g., De Haas et al., Biochim. Biophys. Ada, 116, 114-124 (1966) and Inoue et al., Chem. Pharm. Bull. 11, 1150-1156 (1963)). Although the schemes were suitable for the preparation of small quantities of cardiolipin, those were unattractive for the routine preparation of larger quantities due to the many steps involved, the requirement for careful purification of intermediates and the use of highly photosensitive silver salt derivatives and unstable iodo intermediates.
[0007] Phosphate triesters and phosphoramidite esters have been used extensively in nucleic acid synthesis to form phosphate linkages, and to a lesser extent in phospholipid synthesis (see, e.g., Browne et al., J. Chem. Soc. Perkin Trans, 1, 653-657 (2000)). In this respect, Browne et al., supra, describes the preparation of phospholipid analogs, particularly phosphorylcholine analogs, using phosphoramidite methodologies. The phosphatidylinositols PtdIns(4,5)P2 and PtdIns(3,4,5)P3, and derivatives thereof, have been prepared using a variety of phosphoramidite reagents, including N, N- diisopropylphosphoramidite (see, e.g., Watanabe et al., Tetrahedron Lett. 35, 123-124 (1994)), difluorenyl phosphoramidite (see, e.g., Watanabe et al., Tetrahedron Lett. 38, 7407-7410 (1997)), and a reagent produced by reacting a diacylglycerol with (benzyloxy)(N, N-diisopropylamino)chlorophosphine (see, e.g., Chen et al., J. Org. Chem., 61, 6305-6312 (1996) and Prestwich et al, Ace. Chem. Res., 29, 503-513 (1996)). In addition, phosphotriester analogs of PtdIns(4,5)P2 and PtdIns(3,4,5)P3 have been prepared utilizing the phosphoramidite reagent 2-cyano-ethyl N, N, N, N- tetraisopropylphosphorodiamidite (see, e.g., Gu et al, J. Org. Chem, 61, 8642-8647 (1996)). Moreover, Murakami et al., J. Org. Chem, 64, 648-651 (1999) describe the synthesis of phosphatidyl glycerol from 2,5-diben2yl-D-mannitol utilizing methyl tetraisopropylphosphorodiamidite as a phosphorylating agent. The use of phosphate triesters and phosphoramidite esters in preparing phospholipids such as cardiolipin, particularly cardiolipin species having varying fatty acid chain lengths, however, is not well established.
[0008] New synthetic methods are needed that can be used to prepare large quantities of saturated and unsaturated cardiolipin species having varying fatty acid chain length, particularly "short chain cardiolipins". Such methods would increase the availability of a wider variety of cardiolipin species and would diversify the lipids available for development of new liposomal formulations containing active agents, which will have more defined compositions than those currently available.
[0009] The invention provides such methods and compositions. These and other advantages of the invention, as well as additional inventive features, will be evident from the description of the invention provided herein.
BRIEF SUMMARY OF THE INVENTION [0010] The invention provides novel synthetic methodologies for preparing cardiolipin having varying fatty acids and/or alkyl chains with varying length and saturation/unsaturation. The methods comprises of (a) reacting an optically pure 1,2-O- diacyl-OT-glycerol or l,2-O-dialkyl-jn-glycerol with one or more phosphoramidite reagent(s) or one or more phosphate triester(s), (b) coupling the product of (a) with a 2- protected glycerol, wherein a protected cardiolipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared. The invention also provides a method for preparing cardiolipin having varying fatty acid chain lengths comprising (a) reacting a 2-O-protected glycerol with one or more phosphoramidite reagents, wherein a phosphorylating agent is produced, (b) reacting the phosphorylating agent with an optically pure 1,2-O-diacyl-srø-glycerol or l,2-O-dialkyl-,sn-glycerol, wherein a protected cardiolipin is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared. [0011] The cardiolipin prepared by the present methods can be incorporated into liposomes, which can also include active agents such as hydrophobic or hydrophilic drugs, antisense nucleotides or diagnostic agents. Such liposomes can be used to treat diseases or in diagnostic and/or analytical assays.
BRIEF DESCRIPTION OF THE DRAWINGS [0012] Figure 1 depicts the general structure of cardiolipin.
[0013] Figure 2 depicts one scheme for synthesizing cardiolipin. [0014] Figure 3 depicts an alternative synthetic scheme for cardiolipin.
[0015] Figure 4 depicts an alternative synthetic scheme for cardiolipin.
[0016] Figure 5 depicts an alternative synthetic scheme for cardiolipin.
[0017] Figure 6 depicts an alternative synthetic scheme for cardiolipin ether analogs.
[0018] Figure 7 depicts an alternative synthetic scheme for cardiolipin ether analogs.
DETAILED DESCRIPTION OF THE INVENTION
[0019] The present invention describes methods for the synthesis of cardiolipin variants and analogs having the general formulas I, II, and III, as well as compositions containing such variants and analogs.
Figure imgf000005_0001
I
Figure imgf000005_0002
II
Figure imgf000005_0003
III
In Formula III, Yj. andY2 are the same or different and are -O-C(O)-, -O-, -S-, -NH-C(O)- or the like. In Formulas I, II and III, Rt and R2 are the same or different and are H, saturated and/or unsaturated alkyl group, preferably a C2to C34 saturated and/or unsaturated alkyl group. In Formula III, R3 is (CH2)n and n = 0 - 15. In Formula III, R4 is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, a peptide, dipeptide, polypeptide, protein, carbohydrate (such as glucose, mannose, galactose, polysaccharide and the like), lieterocyclic, nucleoside, polynucleotide and the like. In Formula III, R5 is a linker, which may (or may not be) added in the molecule depending on the need and applications. However, where added, R5 can comprise alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkoxy, polyalkyloxy (such as pegylated ether of containing from about 1 to 500 alkyloxymers (and can have at least about 10 alkyloxy mers, such as at least about 50 alkyloxy mers or at least about 100 alkyloxy mers, such as at least about 200 alkyloxy mers or at least about 300 alkyloxy mers or at least about 400 alkyloxy mers), substituted polyalkyloxy and the like), a peptide, dipeptide, polypeptide, protein, carbohydrate such as glucose, mannose, galactose, polysaccharides and the like. In Formulas I, II and III, X is hydrogen or a non-toxic cation, preferably ammonium, sodium, potassium, calcium, barium ion and the like.
[0020] The term "alkyl" encompasses saturated or unsaturated straight-chain and branched-chain hydrocarbon moieties. The term "substituted alkyl" comprises alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy (of a lower alkyl group), mercapto (of a lower alkyl group), cycloalkyl, substituted cycloalkyl, halogen, cyano, nitro, amino, a ido, imino, thio, -C(O)H, acyl, oxyacyl, carboxyl, and the like. [0021] In the most preferred embodiment Y\ and Y2 in Formula III are -O-C(O)- or -O-. R3 is most preferably is CH2. Also, in Formulas I, II, and III, Ri and R2 are the same and are a C2 to C13 saturated and/or unsaturated alkyl group, more preferably between 4 and 14 carbon atoms (such as between about 6 and 12 carbon atoms). X is most preferably is hydrogen or ammonium ion. In the absence of linker (R5), it gives the general structure of cardiolipin (Figure 1).
[0022] The invention provides a method for preparing cardiolipin or an analogue thereof of Formulas I, II, or III, comprising reacting an alcohol of the formula VIII with one or more phosphoramide reagents and 2-O-protected glycerol or 2-O-subsituted glycerol VI in the presence of an acid catalyst.
Figure imgf000006_0001
Y in formula VI is a hydroxyl protecting group, preferably alkyl group or the like, or a silyl protecting group. In Formula VHI, Ri, R2, R3, Yi, and Y2, can be as indicated above with respect to Formulas I, II, or πi. In accordance with the inventive method, the acid catalyst can be any suitable catalyst that can facilitate the reaction. Examples of such catalysts include 4,5-dichloroimidazole, lH-tetrazole, 5-(4-nitrophenyl)-lH-tetrazole, 5-(3,5- dinitrophenyl)-lH-tetrazole, N-methylimidazolium triflate, and N-methylimidazolium perchlorate, 4,5-dicyanoimidazole, 5-ethylthio-lH-tetrazole, and 5-methylthio-lH-tetrazole. Preferred catalysts are 4,5-dichloroimidazole orlH-tetrazole. In accordance with the inventive method, the coupling phosphoramidites can have formula IV or V:
Figure imgf000007_0001
IV V
[0023] In another embodiment, the invention provides a method for preparing cardiolipin or an analogue thereof of formulas I, II, or III; comprising reacting 2-O protected glycerol with one or more phosphotriesters in the presence of pyridinium tribromide. Preferred phosphotriesters can be produced by reacting an alcohol of formula VIII with phosphoramidite of general formula VII.
Figure imgf000007_0002
VII
[0024] X in Formulas IV, V, or VII is a phosphate protecting group, preferably a benzyl group or 2-cyanoethyl or silyl group. Other examples of suitable protecting groups include alkyl phosphates including ethyl, cyclohexyl, t-butyl; 2-substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2-(methyldiphenylsilyl)ethyl, 2- (trimethylsilyι)ethyl, 2-(triphenylsilyl)ethyl; haloethyl phosphates including 2,2,2- trichloroethyl, 2,2,2-tribromoethyl, 2,2,2-trifluoroethyl; benzyl phosphates including 4- chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates. [0025] A general sequence of reactions for the synthesis of compound of invention is illustrated in Figures 2 & 3. The present invention provides a method for preparing cardiolipin I having varying fatty acid chain lengths comprising (a) reacting an optically pure l,2-O-diacyl--f«-glycerol 2 with one or more phosphoramidite reagent(s)of the general formula IV (figure 2) or V (figure 3) (b) coupling the product of (a) 3 with a 2-O-protected glycerol VI in a chlorinated solvent (for example dichloromethane, chloroform or like) followed by oxidation with m-chloroperoxybenzoic acid (m-CPBA) results in the production of a protected cardiolipin 4. Thereafter, deprotecting the protected cardiolipin followed by conversion to ammonium salt will result in the production of cardiolipin 1 (ammonium salt).
[0026] For reaction with optically pure 1 ,2-O-diacyl-OT-glycerol 2, any suitable phosphoramidite reagent or methodology may be used, such as is described in, for example Browne et al., supra. Examples of suitable phosphoramidite reagents include (benzyloxyXN N-diisopropylamino)chlorophosphine (see, e.g., Prestwich et al. J. Am. Chem. Soc. 1991, 113, 1822-1825), benzyloxybis (diisopropylamino) phosphine (see, e.g., Dreef et al. Tetrahedron Lett. 1988, 29, 6513-6516), 2-cyanoethyl-N, N N N- tetraisopropylphosphoramidite (see, e.g., Browne et al. J. Chem. Soc. Perkin Trans. 1. 2000, 653-657.), (2-cyanoethyl)(N,N-diisopropylamino)chlorophosphine (see, e.g., Prestwich et al. J. Org. Chem. 1998, 63, 6511-6522), difluorenyl diisopropylphosphoramidite (see, e.g., Watanabe et al. Tetrahedron Lett. 1997, 38, 7407-7410), methyl-N N, N N tetraisopropylphosphorodiamidite (see, e.g., Murakami et al. J. Org. Chem. 1999, 64, 648- 651), dimethyl Ν, Ν-diisopropylphosphoramidite (see, e.g., Watanabe et al. Tetrahedron Lett. 1993, 34, 497-500), dibenzyl diisopropylphosphoramidite (see, e.g., Watanabe et al. Tetrahedron Lett. 2000, 41, 8509-8512), di-tert-butyl-NN-diisopropylphosphoramidite (see, e.g., Lindberg et al. J. Org. Chem.2002, 67, 194-199.), 2-(diρhenylmethylsilyl)ethyl- N N N N-tetraisopropylphosphoramidite (see, e.g., Chevallier et al. Org. Lett 2000, 2, 1859-1861), (Ν-trifluoroacetylamino) butyl and (Ν-trifluoroacetylamino) pentyl-N, N N N- tetraisopropylphosphoramidites (see, e.g., wilk et al. J. Org. Chem. 1997, 62, 712-6713). [0027] Another embodiment of the present invention is depicted in Figure 4. In this method the optically pure l,2-O-diacyl-,s72-glyeerol 2 can be phosphorylated using phosphoramidite VII to yield phosphite triesters 5 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy 1,3-propanediol or 2- levulinoyl-1. 3-propanediol using pyridinium perbromide and phosphoniurn salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin 4. The preferred coupling reagent in this context of synthetic methods is dibenzyl diisopropylphosphoramidite.
[0028] In an alternative strategy set forth in Figure 5, the inventive method comprises (a) reacting a 2-O-protected glycerol VI with one or more phosphoramidite reagents IV or V, wherein a phosphorylating agent 6 is produced, (b) reacting the phosphorylating agent 6 with an optically pure l,2-O-diacyl-s«-glycerol 2 followed by oxidation with m-CPBA, wherein a protected cardiolipin 4 is produced, and (c) deprotecting the protected cardiolipin, such that the cardiolipin is prepared. Suitable phosphoramidite reagents and 2-O-protected glycerols for use in this aspect of the inventive method are described above. [0029] Another embodiment of the present invention, represented in Figure 6 leads to ether analogs of cardiolipin, wherein the acyl groups are replaced by alkyl chain. Accordingly (a) 1,2-O-dialkyl-ΛΗ-glycerol 7 is treated with phosphoramidites IV or V wherein a phosphorylating agent 8 is produced, (b) reacting the phosphorylating agent with a 2-O-protected glycerol VI followed by oxidation, wherein a protected cardiolipin 9 is produced, and (c) deprotecting the protected cardiolipin, such that the ether analog of cardiolipin 10 is produced. [0030] Another embodiment of the present invention is depicted in Figure 7. In this method the optically pure 1,2-O-dialkyl-OT-glycerol 7 can be phosphorylated using phosphoramidite VII to yield phosphite triesters 11 which can be coupled with any suitable 2-O-protected glycerol VI, such as, for example, benzyloxy 1,3-propanediol or 2- levulinoyl-1, 3-propanediol using pyridinium perbromide and phosphonium salt methodology (see, e.g., Watanabe et al., supra) to get protected cardiolipin ether analog 9. The preferred coupling reagent in this context of synthetic methods is dibenzyl diisopropylphosphoramidite.
[0031] The invention described above is an elegant and efficient method of synthesizing cardiolipin. The routes are short and proceed in good overall yield. The deprotection can be accomplished by a method depending on the protecting group. For example a benzyl group can be removed by catalytic hydrogenolysis or by treatment with Nal, 2-cyanoethyl and fluorenylmethyl groups by treatment with a tertiary base such as triethylamine, a silyl group can be deprotected with fluoride ion or acidic medium, a levulinoyl group by hydrazinolysis.
[0032] The synthetic methods described herein can be modified in any suitable manner. For example, phosphoramidites and phosphate esters can be prepared using a variety of acid catalysts, including 4,5-dichloroimidazole (see, e.g., Browne et al.), 5-(4-nitrophenyl)-lH- tetrazole, 5-(3,5-dinitrophenyl)-lH-tetrazole, N-methylimidazolium triflate, and N- methylimidazolium perchlorate (see, e.g., Moriguchi et al.). Likewise, tert- butylhydroperoxide can be used as an alternative oxidant. The described methods can be further modified in any suitable manner known in the art.
[0033] The inventive method can be used to prepare cardiolipin species comprising fatty acid /alkyl chains of varying length and saturation/unsaturation. The general structure of a phospholipid fatty acid comprises a hydrocarbon chain and a carboxylic acid group. In general, the length of the fatty acid hydrocarbon chain ranges from about 2 to about 34 carbon atoms and can be saturated or unsaturated. However, the carbon chain is more typically between about 12 and about 24 carbon atoms. In some embodiments, it is desirable for the hydrocarbon chain to comprise, for example, at least about 5 carbon atoms or at least about 10 carbon atoms or even at least about 15 carbon atoms. Typically, the length of the fatty acid hydrocarbon is less than about 24 carbon acids, such as less than about 24 carbon atoms, or even less than about 20 carbon atoms. [0034] The invention also provides a cardiolipin or cardiolipin analogue prepared in accordance with the inventive method. Most preferably, the cardiolipin prepared by the inventive method comprises a short fatty acid chain (i.e., a "short chain cardiolipin"), and the invention provides a short chain cardiolipin. A short fatty acid chain comprises between about 2 and between about 14 carbon atoms, and can have between about 4 (or about 6) and about 12 carbon atoms, such as between about 8 and about 10 carbon atoms. Alternatively, the cardiolipin produced by the inventive method can comprise a long chain fatty acid chain (i.e., a "long chain cardiolipin"). A long fatty acid chain comprises between about 14 and about 34 carbon atoms, such as between about 14 (or between about 20) and about 24 carbon atoms. The inventive method is not limited to the production of short or long chain cardiolipin species exclusively. Indeed, a cardiolipin containing fatty acid alkyl chains of intermediate length can also be prepared by the inventive method. [0035] Phospholipid fatty acids typically are classified by the number of double and/or triple bonds in the hydrocarbon chain (i.e., unsaturation). A saturated fatty acid does not contain any double or triple bonds, and each carbon in the chain is bound to the maximum number of hydrogen atoms. The degree of unsaturation of a fatty acid depends on the number of double or triple bonds present in the hydrocarbon chain. In this respect, a monσunsaturated fatty acid contains one double bond, whereas a polyunsaturated fatty acid contains two or more double bonds (see, e.g., Oxford Dictionary of Biochemistry and Molecular Biology, rev. ed., A.D. Smith (ed.), Oxford University Press (2000), and Molecular Biology of the Cell, 3rd ed., B.A. Alberts (ed.), Garland Publishing, New York (1994)). The fatty acid chains of the cardiolipin are prepared by the inventive method, whether short or long, also can be saturated or unsaturated.
[0036] The described methods can be used to prepare a variety of novel cardiolipin molecules. For example, the methods can be used to prepare cardiolipin variants in pure form containing short or long fatty acid side chains. Preferred fatty acids range from carbon chain lengths of about C2 to C3 , preferably between about C and about C2 , and include tetranoic acid (C4:o), pentanoic acid (C5:o), hexanoic acid (Cδ-.o heptanoic acid (C7:o), octanoic acid (C8:o), nonanoic acid (C9:o), decanoic acid (Cιo:o), undecanoic acid (C11:o), dodecanoic acid (Cι2:o), tridecanoic acid (C13:o), tetradecanoic (myristic) acid (Cι :o), pentadecanoic acid (Ci5:o), hexadecanoic (palmatic) acid (Ci6:o), heptadecanoic acid (Cπ-o), octadecanoic (stearic) acid (Cι8:o), nonadecanoic acid (C1 :o), eicosanoic (arachidic) acid (C20:o)5 heneicosanoic acid (C21:o), docosanoic (behenic) acid (C22:o), tricosanoic acid (C23:o), tetracosanoic acid (C2 :o), 10-undecenoic acid (Ci ), 11-dodecenoic acid (Cι2:ι), 12- tridecenoic acid (C13:ι), myristoleic acid (C14;1), 10-pentadecenoic acid (C15:1), palmitoleic acid (Ciβ.i , oleic acid (C18;ι), linoleic acid (Cι8:2), linolenic acid (Cis.s), eicosenoic acid (C201), eicosdienoic acid (C2o:2), eicosatrienoic acid (C2o:3), arachidonic acid
Figure imgf000010_0001
eicosatetraenoic acid), and c/'s-5,8,ll,14,17-eicosapentaenoic acid, among others. For ether analogs, the alkyl chain will also range from C2 to C3 preferably between about C and about C2 . Other fatty acid chains also can be employed as Ri and or R2 substituents. Examples of such include saturated fatty acids such as ethanoic (or acetic) acid, propanoic (or propionic) acid, butanoic (or butyric) acid, hexacosanoic (or cerotic) acid, octacosanoic (or montanic) acid, triacontanoic (or melissic) acid, dotriacontanoic (or lacceroic) acid, tetratriacontanoic (or gheddic) acid, pentatriacontanoic (or ceroplastic) acid, and the like; monoefhenoic unsaturated fatty acids such as trcms^-butenoic (or crotonic) acid, cis-2- butenoic (or isocrotonoic) acid, 2-hexenoic (or isohydrosorbic) acid, 4-decanoic (or obtusilic) acid, 9-decanoic (or caproleic) acid, 4-dodecenoic (or linderic) acid, 5-dodecenoic (or denticetic) acid, 9-dodecenoic (or lauroleic) acid, 4-tetradecenoic (or tsuzuic) acid, 5- tetradecenoic (or physeteric) acid, 6-octadecenoic (or petroselenic) acid, trans-9- octadecenoic (or elaidic) acid, trans-11-octadecenoic (or vaccinic) acid, 9-eicosenoic (or gadoleic) acid, 11-eicosenoic (or gondoic) acid, 11-docosenoic (or cetoleic) acid, 13- decosenoic (or erucic) acid, 15-tetracosenoic (or nervonic) acid, 17-hexacosenoic (or ximenic) acid, 21-triacontenoic (or lumequeic) acid, and the like; dienoic unsaturated fatty acids such as 2,4-pentadienoic (or β-vinylacrylic) acid, 2,4-hexadienoic (or sorbic) acid, 2,4-decadienoic (or stillingic) acid, 2,4-dodecadienoic acid, 9,12-hexadecadienoic acid, cis- 9, cis-12-octadecadienoic (or α-linoleic) acid, trans-9, trans-12-octadecadienoic (or linlolelaidic) acid, trans- 10, trans- 12-octadecadienoic acid, 11,14-eicosadienoic acid, 13,16- docosadienoic acid, 17,20-hexacosadienoic acid and the like; trienoic unsaturated fatty acids such as 6,10,14-hexadecatrienoic (or hiragonic) acid, 7,10,13-hexadecatrienoic acid, cis-6, cis-9- cw-12-octadecatrienoic (or γ-linoleic) acid, trans-S, trans-10- trans-12- octadecatrienoic (or β-calendic) acid, cis-8, trans-10- cw-12-octadecatrienoic acid, cis-9, cis-\2- cw-15-octadecatrienoic (or α-linolenic) acid, trans-9, trans-\2- trans-15- octadecatrienoic (or -linolenelaidic) acid, cis-9, trans-11- tr n^-13-octadecatrienoic (or -eleostearic) acid, trans-9, trans-11- tr< ϊ-13-octadecatrienoic (or β-eleostearic) acid, cis-9, trans-11- cw-13-octadecatrienoic (or punicic) acid, 5,8,11-eicosatrienoic acid, 8,11,14-eicosatrienoic acid and the like; tetraenoic unsaturated fatty acids such as 4,8,11,14-hexadecatetraenoic acid, 6,9,12,15- hexadecatetraenoic acid, 4,8,12,15- octadecatetraenoic (or moroctic) acid, 6,9,12,15- octadecatetraenoic acid, 9,11,13,15- octadecatetraenoic (or - or β-parinaric) acid, 9,12,15,18-octadecatetraenoic acid, 4,8,12,16-eicosatetraenoic acid, 6,10,14,18-eicosatetraenoic acid, 4,7,10,13- docasatetraenoic acid, 7,10,13,16-docosatetraenoic acid, 8,12,16,19-docosatetraenoic acid and the like; penta- and hexa-enoic unsaturated fatty acids such as 4,8,12,15,18- eicosapentaenoic (or timnodonic) acid, 4,7,10,13,16-docosapentaenoic acid, 4,8,12,15,19- docosapentaenoic (or clupanodonic) acid, 7,10,13,16,19-docosapentaenoic, 4,7,10, 13,16,19-docosahexaenoic acid, 4,8,12,15, 18,21-tetracosahexaenoic (or nisinic) acid and the like; branched-chain fatty acids such as 3-methylbutanoic (or isovaleric) acid, 8- methyldodecanoic acid, 10-methylundecanoic (or isolauric) acid, 11-methyldodecanoic (or isoundecylic) acid, 12-methyltridecanoic (or isomyristic) acid, 13-methyltetradecanoic (or isopentadecylic) acid, 14-mefhylpentadecanoic (or isopalmitic) acid, 15- methylhexadecanoic, 10-methylheptadecanoic acid, 16-methylheptadecanoic (or isostearic) acid, 18-methylnonadecanoic (or isoarachidic) acid, 20-methylheneicosanoic (or isobehenic) acid, 22-methyltricosanoic (or isolignoceric) acid, 24-methylpentacosanoic (or isocerotic) acid, 26-methylheptacosanoic (or isomonatonic) acid, 2,4,6- trimefhyloctacosanoic (or mycoceranic or mycoserosic) acid, 2-methyl-c/>s'-2- butenoic(angelic)acid, 2-methyl-tr rø-2-butenoic (or tiglic) acid, 4-methyl-3-pentenoic (or pyroterebic) acid and the like.
[0037] The term 'hydroxyl protecting group' used herein the invention refers to the commonly used protecting groups disclosed by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999). Such protecting groups include methyl ether, substituted methyl ethers including methoxymethyl, benzyloxymethyl, ^-methoxybenzyloxymethyl, 2-methoxyethoxymethyl, tetrahydropyranyl, tetrahydrofuranyl ethers; substituted ethyl ethers like 1-ethoxyethyl, 1- methyl-1-benzyloxy ethyl, allyl, propargyl; benzyl and substituted benzyl ethers including p- methoxybenzyl, 3,4-dimethoxybenzyl, triphenylmethyl; silyl ethers including trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, diphenylmethylsilyl; esters including formate, acetate, chloroacetate, dichloroacetate, trichloroacetate, benzoate, levulinylate and carbonates. [0038] The term 'phosphate protecting group' used herein the invention refers to the commonly used protecting groups described by T. W. Greene and P. G. Wuts, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons, New York (1999). Such protecting groups include alkyl phosphates including methyl, ethyl, cyclohexyl, t-butyl; 2- substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2- (methyldiphenylsilyl)ethyl, 2-(trimethylsilyl)ethyl, 2-(triphenylsilyl)ethyl; haloethyl phosphates including 2,2,2-trichloroethyl, 2,2,2-tiibromoethyl, 2,2,2-trifluoroethyl; benzyl phosphates including 4-chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates. [0039] The cardiolipin molecules described herein and cardiolipins produced by the inventive method can be used in lipid formulations, such as liposomal compositions. Complexes, emulsions and other formulations including the inventive cardiolipin also are within the scope of the present invention. Such formulations according to the present invention can be prepared by any suitable technique. The invention provides a method for preparing a liposome or other lipid composition, comprising preparing a cardiolipin or cardiolipin analogue as described herein and including the cardiolipin or cardiolipin analogue in a lipid formulation, such as a liposome. The invention also includes such lipid compositions including the inventive cardiolipin and/or cardiolipin analogues.
[0040] In addition to the inventive cardiolipin, the liposomal composition, complex, emulsion and the like can include other lipids. Thus, for example, the composition can include one or more phosphatidylcholines, such as, for example, dimyristoylphosphatidylcholine, distearoylphosphatidylcholine, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof. Alternatively or additionally, the composition can include one or more phosphatidylglycerols, such as dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, and mixtures thereof. Alternatively or additionally, the composition can include one or more sterols, such as cholesterol, derivatives of cholesterol, coprostanol, cholestanol, cholestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof. Preferably, in addition to the cardiolipin or cardiolipin analogue, the composition includes a phosphatidylcholine, a sterol, and a tocopherol (e.g., α-tocopherol). [0041] In addition to the cardiolipin and, optionally, other lipids, the composition also can include stabilizers, absorption enhancers, antioxidants, phospholipids, biodegradable polymers and medicinally active agents among other ingredients. In some embodiments, it is preferable for the inventive composition, especially liposomal composition, to include one or more targeting agents, such as carbohydrate or a protein or other ligand that binds to a specific substrate, for example, that recognize cellular receptors. The inclusion of such agents (such as a carbohydrate or one or more proteins selected from groups of proteins consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands such as an antibody to a cellular receptor and mixtures thereof) can facilitate targeting a liposome to a predetermined tissue or cell type. [0042] For medicinal use, the composition also can include one or more active agents. A single active agent can be included, or a mixture of active agents (e.g., two or more active agents) can be included within the composition. Active agents (or "drugs") can be present in any suitable manner in the composition. For example, they can be complexed with the cardiolipin or cardiolipin analogue in the composition. Additionally, or alternatively, one or more active agents can be entrapped within liposomes, when the composition is a liposomal composition.
[0043] Active agents which are compatible with the present invention include, for example, agents which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synaptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, the alimentary and excretory systems, the histamine system and the central nervous system. Suitable agents may be selected from, for example, proteins, enzymes, hormones, nucleotides (including sense and antisense oligonucleotides (see, e.g., U.S. Patent 6,126,965), polynucleotides, nucleoproteins, polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids. Active agents can be analgesics, anesthetics, anti-arrythmic agents, antibiotics, antiallergic agents, antifungal agents, anticancer agents, anticoagulants, antidepressants, antidiabetic agents, anti-epilepsy agents, anti-inflammatory corticosteroids, agents for treating Alzheimers or Parkinson's disease, antiulcer agents, anti-protozoal agents, anxiolytics, thyroids, anti-thyroids, antivirals, anoretics, bisphosphonates, cardiac inotropic agents, cardiovascular agents, corticosteroids, diuretics, dopaminergic agents, gastrointestinal agents, hemostatics, hypercholesterol agents, antihypertensive agents (e.g., dihydropyridines), antidepressants, and cox-2 inhibitors, immunosuppressive agents, anti- gout agents, anti-malarials, steroids, terpinoids, triterpines, retinouds; anti-ulcer H2-receptor antagonists, hypoglycemic agents, moisturizers, cosmetics, anti-migraine agents, antimuscarinic agents, antiinflammatory agents, such as agents for treating rheumatology, arthritis, psoriasis, inflammatory bowel disease, Crohn's disease; or agents for treating demyelinating diseases including multiple sclerosis, ophthalmic agents, vaccines (e.g., against pneumonia, hepatitis A, hepatitis B, hepatitis C, cholera toxin B subunit, influenza virus, typhoid, plasmodium falciparun, diptheria, tetanus, HSN, tuberculosis, HIN, SARS virus, pordetela pertussis, measles, mumps and rubella vaccine (MMN), bacterial toxoids, vaccinea virus, adenovirus, canary, polio virus, bacillus calmette guerin (BCG), klebsiella pneumonia, etc.), histamine receptor antagonists, hypnotics, kidney protective agents, lipid regulating agents, muscle relaxants, neuroleptics, neurotropic agents, opioid agonists and antagonists, parasympathomimefics, protease inhibitors, prostglandins, sedatives, sex hormones (e.g., estrogen, androgen), stimulants, sympathomimetics, vasodilators and xanthins and synthetic analogs of these species. The therapeutic agents can be nephrotoxic, such as cyclosporins and amphotericin B, or cardiotoxic, such as amphotericin B and paclitaxel. Exemplary anticancer agents include melphalan, chlormethine, extramustinephosphate, uramustine, ifosfamide, mannomustine, trifosfamide, streptozotocin, mitobronitol, mitoxantrone (see., e.g., published international patent application WO 02/32400), methotrexate, fluorouracil, cytarabine, tegafur, idoxide, taxanes (e.g., taxol, paclitaxel, etc., see published international patent application WO 00/01366), daunomycin, daunorubicin, bleomycin, amphotericin, carboplatin, cisplatin, paclitaxel, BCΝU, vinca alkaloids (e.g., vincristine, vinorelbine (see, e.g., published international patent application WO 03/018018), and the like) camptothecin and derivatives thereof (e.g., SΝ38 (see, e.g., published international patent application WO 02/058622), irinotecan (see, e.g., published international patent application WO 03/030864), and the like), anthracyclines, antibodies, cytoxines, doxorubicin, etopside, cytokines, ribozymes, interferons, oligonucleotides and functional derivatives of the foregoing. Additional examples of drugs which may be delivered according to the method include, prochlorperzine edisylate, ferrous sulfate, aminocaproic acid, mecamylamine hydrochloride, procainamide hydrochloride, amphetamine sulfate, methamphetamine hydrochloride, benzamphetamine hydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride, bethanechol chloride, methacholine chloride, pilocarpine hydrochloride, atropine sulfate, scopolamine bromide, isopropamide iodide, tridihexethyl chloride, phenformin hydrochloride, metliylphenidate hydrochloride, theophylline cholinate, cephalexin hydrochloride, diphenidol, meclizine hydrochloride, prochlorperazine maleate, phenoxybenzamine, thiethylperzine maleate, anisindone, diphenadione erythrityl tetianitrate, digoxin, isoflurophate, acetazolamide, methazolamide, bendroflumethiazide, chloropromaide, tolazamide, chlormadinone acetate, phenaglycodol, allopurinol, aluminum aspirin, methotrexate, acetyl sulfisoxazole, erythromycin, hydrocortisone, hydrocorticosterone acetate, cortisone acetate, dexamethasone and its derivatives such as betamethasone, triamcinolone, methyltestosterone, 17-S-estradiol, ethinyl estradiol, ethinyl estradiol 3 -methyl ether, prednisolone, 17α-hydroxyprogesterone acetate, 19- norprogesterone, norgestrel, norethindrone, noretliisterone, norethiederone, progesterone, norgesterone, norethynodrel, aspirin, indomethacin, naproxen, fenoprofen, sulindac, indoprofen, mtroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol, alprenolol, cimetidine, clonidine, imipramine, levodopa, chlorpromazine, methyldopa, dihydroxyphenylalanine, theophylline, calcium gluconate, ketoprofen, ibuprofen, cephalexin, erythromycin, haloperidol, zomepirac, ferrous lactate, vincamine, diazepam, phenoxybenzamine, diltiazem, milrinone, mandol, quanbenz, hydrochlorothiazide, ranitidine, flurbiprofen, fenufen, fluprofen, tolmetin, alclofenac, mefenamic, flufenamic, difuinal, nimodipine, nitrendipine, nisoldipine, nicardipine, felodipine, lidoflazine, tiapamil, gallopamil, amlodipine, mioflazine, lisinolpril, enalapril, enalaprilat captopril, ramipril, famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil, chlordiazepoxide, diazepam, amitriptyline, and imipramine. Further examples are proteins and peptides which include, but are not limited to, bone morphogenic proteins, insulin, colchicine, glucagon, thyroid stimulating hormone, parathyroid and pituitary hormones, digestive hormones, calcitonin, renin, prolactin, corticotrophin, thyrotropic hormone, follicle stimulating hormone, chorionic gonadotropin, gonadotropin releasing hormone, bovine somatotropin, porcine somatotropin, oxytocin, vasopressin, GRF, somatostatin, lypressin, pancreozymin, luteinizing hormone, LHRH, LHRH agonists and antagonists, leuprolide, interferons (e.g., consensus interferon, interferon α-2a, interferon cc-2b, α-, β-, or γ- interferons), interleuldns, growth hormones such as human growth hormone and its derivatives such as methione-human growth hormone and des-phenylalanine human growth hormone, bovine growth hormone and porcine growth hormone, fertility inhibitors such as the prostaglandins, fertility promoters, growth factors such as insulin-like growth factor, coagulation factors, pancreas hormone releasing factor, analogs and derivatives of these compounds, and pharmaceutically acceptable salts of these compounds, or their analogs or derivatives. The therapeutic agent can be a mixture of drugs or agents (e.g., two or more agents) that can be beneficially co-administered in the liposome formulation.
[0044] Generally, liposomes can have a net neutral, negative or positive charge. For example, positive liposomes can be formed from a solution containing phosphatidylcholine, cholesterol, cardiolipin and enough stearylamine to overcome the net negative charge of cardiolipin. Negative liposomes can be formed from solutions containing phosphatidyl choline, cholesterol, and/or cardiolipin variants prepared by the methods described herein. [0045] The liposomes of the present invention can be multi or unilamellar vesicles depending on the particular composition and procedure to make them. Liposomes can be prepared to have substantially homogeneous sizes in a selected size range, such as about 1 micron or less, or about 500 nm or less, about 200nm or less, or about lOOnm or less. One effective sizing method involves extruding an aqueous suspension of the liposomes through a series of polycarbonate membranes having a selected uniform pore size; the pore size of the membrane will correspond roughly with the largest sizes of liposomes produced by extrusion through that membrane. [0046] The liposomal (or other lipid) composition can be in any desired form. For example, for pharmaceutical use, the composition can be ready for administration to a patient. Alternatively, the composition can be in dried or lyophilized form. Where the composition is dried or lyophilized, preferably the composition includes a cryoprotectant as well. Suitable cryoprotectants include, for example, sugars such as tiehalose, maltose, lactose, sucrose, glucose, and dextran, with the most preferred sugars from a performance point of view being tiehalose and sucrose. Other more complicated sugars can also be used, such as, for example, aminoglycosides, including streptomycin and dihydrostreptomycin. [0047] Any suitable method can be employed to form the liposomes. For example, lipophilic liposome-forming ingredients, such as phosphatidylcholine, a cardiolipin prepared by the methods described above, cholesterol and α-tocopherol can be dissolved or dispersed in a suitable solvent or combination of solvents and dried. Suitable solvents include any non-polar or slightly polar solvent, such as t-butanol, ethanol, methanol, chloroform, or acetone that can be evaporated without leaving a pharmaceutically unacceptable residue. Drying can be by any suitable means such as by lyophilization. The dehydration is typically achieved under vacuum and can take place either with or without prior freezing of the liposome preparation. Hydrophilic ingredients can be dissolved in polar solvents, including water. [0048] Mixing the dried lipophilic ingredients with the hydrophilic mixture can form liposomes. Mixing the polar solution with the dry lipid film can be by any means that strongly homogenizes the mixture. Nortexing, magnetic stirring and/or sonicating can effect the homogenization. [0049] Where active agents (or a mixture of active agents) are included in the liposomes, the invention provides a method for retaining a drug in a liposome. In accordance with the method, cardiolipin or cardiolipin analogue is prepared as described herein, and the cardiolipin or cardiolipin analogue and a drug or drugs (e.g., an active agent a mixture of active agents) is included within a liposome. For example, active agent(s) can be dissolved or dispersed in a suitable solvent and added to the liposome mixture prior to mixing. Typically hydrophilic active agents will be added directly to the polar solvent and hydrophobic active agents will be added to the nonpolar solvent used to dissolve the other ingredients but this is not required. The active agent could be dissolved in a third solvent or solvent mix and added to the mixture of polar solvent with the lipid film prior to homogenizing the mixture.
[0050] Liposomes can be coated with a biodegradable polymers such as sucrose, epichlorohydrin, branched hydrophilic polymers of sucrose, polyethylene glycols, polyvinyl alcohols, methoxypolyethylene glycol, ethoxypolyethylene glycol, polyethylene oxide, polyoxyethylene, polyoxypropylene, cellulose acetate, sodium alginate, Ν,Ν- diefhylaminoacetate, block copolymers of polyoxyethylene and polyoxypropylene, polyvinyl pyrrolidone, polyoxyethylene X-lauryl ether wherein X is from 9 to 20, and polyoxyethylene sorbitan esters.
[0051] Antioxidants can be included in the liposomal composition or other lipid composition. Suitable antioxidants include compounds such as ascorbic acid, tocopherol, and deteroxime mesylate.
[0052] Absorption enhancers can be included in the liposomal composition or other lipid composition. Suitable absorption enhancers include Na-salicylate-chenodeoxy cholate, Na deoxycholate, polyoxyethylene 9-lauryl ether, chenodeoxy cholate- deoxycholate and polyoxyethylene 9-lauryl ether, monoolein, Na tauro-24,25- dihydrofusidate, Na taurodeoxycholate, Na glycochenodeoxycholate, oleic acid, linoleic acid, linolenic acid. Polymeric absorption enhancers can also be included such as polyoxyethylene ethers, polyoxyethylene sorbitan esters, polyoxyethylene 10-lauryl ether, polyoxyethylene 16-lauryl ether, azone (l-dodecylazacycloheptane-2-one). [0053] The inventive lipid (e.g., liposomal) composition also can include one or more pharmaceutically acceptably excipients. For example, pharmaceutically suitable excipients include solid, semi-solid or liquid diluents, fillers and formulation auxiliaries of all kinds. The invention also includes pharmaceutical preparations in dosage units. This means that the preparations are in the form of individual parts, for example vials, syringes, capsules, pills, suppositories, or ampoules, of which the content of the liposome formulation of active agent corresponds to a fraction or a multiple of an individual dose. The dosage units can contain, for example, 1, 2, 3, or 4 individual doses, or 1/2, 1/3, or 1/4 of an individual dose. An individual dose preferably contains the amount of active agent which is given in one administration and which usually corresponds to a whole, a half, a third, or a quarter of a daily dose.
[0054] Tablets, dragees, capsules, pills, granules, suppositories, solutions, suspensions and emulsions, pastes, ointments, gels, creams, lotions, powders and sprays can be suitable pharmaceutical preparations. Suppositories can contain, in addition to the liposomal active agent, suitable water-soluble or water-insoluble excipients. Suitable excipients are those in which the inventive liposomal active agent is sufficiently stable to allow for therapeutic use, for example polyethylene glycols, certain fats, and esters or mixtures of these substances. Ointments, pastes, cream, and gels can also contain suitable excipients in which the liposomal active agent is stable. The composition also can be formulated for injection (e.g., intravenously, interstitially, intratumorally, etc) by the inclusion of one or more excipients (e.g., buffered saline) suitable for injection.
[0055] The active agent or its pharmaceutical preparations can be administered intravenously, subcutaneously, locally, orally, parenterally, intraperitoneally, and/or rectally or by direct injection into tumors or sites in need of treatment by such methods as are known or developed. Cardiolipin and cardiolipin-analog based formulations also can be administered topically, e.g., as a cream, skin ointment, dry skin softener, moisturizer, etc. [0056] The invention provides for the use of the composition to prepare a medicament for the treatment of a disease. In this sense, the invention also provides a method for treating a human or animal disease. In accordance with the inventive method, the inventive composition is exposed to (administered to) a human or animal patient in need of such treatment. Where the composition also includes one or more active agents, the inventive method facilitates delivery of the active agent(s) to the patient. [0057] The method can be used to administer one or more active agents. It is thought to be general for active agents that are stable in the presence of surfactants. Hydrophilic active agents are suitable and can be included in the interior of the liposomes such that the liposome bilayer creates a diffusion barrier preventing it from randomly diffusing throughout the body. Hydrophobic active agents are thought to be particularly well suited for use in the present method because they not only benefit by exhibiting reduced toxicity but they tend to be well solubilized in the lipid bilayer of liposomes.
[0058] Suitable diseases for treatment will depend on the selection of active agents, such as described herein. However a preferred disease is cancer, in which instance, at least one active agent incorporated into the composition is an anticancer agent. Chemotherapeutic agents are well suited for such use. Liposome formulations containing chemotherapeutic agents may be injected directly into the tumor tissue for delivery of the chemotherapeutic agent directly to cancer cells. In some cases, particularly after resection of a tumor, the liposome formulation can be implanted directly into the resulting cavity or may be applied to the remaining tissue as a coating. In cases in which the liposome formulation is administered after surgery, it is possible to utilize liposomes having larger diameters of about 1 micron since they do not have to pass through the vasculature. [0059] In some embodiments, the method can be employed to treat diseases, disorders, or symptoms within patients even where the composition does not contain an active pharmaceutical agent other than cardiolipin. The invention provides for the use of cardiolipin to prepare a medicament to combat or treat such diseases, disorders, or symptoms. The invention further provides a method of treating such diseases, disorders, or symptoms within patients, and the effects of such diseases, disorders, or symptoms by administering to the patient a therapeutically effective amount of cardiolipin. Without being bound by any particular theory, it is believed that cardiolipin provides a beneficial antioxidant effect, which can alleviate the effects of many diseases, disorders, or symptoms. Examples of conditions that can be treated in accordance with the method include, for example, age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders (e.g., acne, psoriasis, eczema, etc.). The method also can be employed to combat the effects of aging. For such use, the cardiolipin can be formulated as a liposomal or non- liposomal formulation (e.g., an emulsion, cream, etc.) as discussed herein and can include, in addition to cardiolipin, one or more pharmaceutically acceptable carriers. In use, the composition can be administered by any suitable route. For example, the composition can be administered dermally, intravenously, or by other desired route of administration. [0060] The invention also is directed to methods of delivering active agents (or mixtures of active agents) to cells. The methods can be carried out by preparing liposomes that include active agents and cardiolipin variants/analogs as synthesized by the above disclosed methods. The liposomes are then delivered to a cell or cells, which can be in vitro or in vivo, as desired. In vivo administration can be achieved as described herein or as otherwise known to those of ordinary skill. For in vitro use, delivery of the active agent(s) can be carried out by adding the composition (e.g., liposomes) to the cell culture medium, for example. [0061] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope. Example 1 Synthesis of Tetramyristoyl Cardiolipin
1A. 2-Benzyl-l,3- bis [(1.2-dimyristoyl-sn-glycero-3)-ρhosphorvι] glycerol dibenzyl ester
Figure imgf000020_0001
Ri, R2 = myristoyl (C1 :o chain)
[0062] A solution of l,2-dimyristoyl-,s,n-glycerol (10 g, 19.53 mmol), benzyl N N- tetraisopropyl phosphoramidite (9.87 g, 29.29 mmol) and lH-tetrazole (65 mL of 0.45 M sol in acetonitrile, 29.29 mmol) in CH2C12 (125 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (1.18 g, 6.47 mmol) in CH2C12 (20 mL) was added followed by 1H- tetrazole (37.7 mL of 0.45 M sol in acetonitrile, 16.85 mmol) and stirred for 3 h. The reaction mixture was cooled to ~40°C and tert-Butyl hydroperoxide (TBHP, 6.4 mL of 5-6 M sol in decane, 32.35 mmol) was added. After stirring at -40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with GH2C12 (250 mL), washed {saturated aq Νa2SO3 (2 x 50 mL), saturated aq NaHCO3 (2 x 50 mL), brine (2 x 50 mL)} dried a2SO ) and concentrated. The residue was purified on Siθ2 column (2:3 EtOAc: hexane) to give 6.68 g (69%) of protected cardiolipin as colorless syrup. TLC (SiO2) hexane/EtOAc (3:2) Rf~ 0.48.1H NMR δ (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 80H), 1.52-1.66 (m, 8H), 2.22- 2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, 10H), 4.22-4.28 (m, 2H), 4.60 (d, J = 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H).
IB. L3- bis [(L2-dimyristoyl-rø-glycero-3yphosρhoryι] lycerol diammonium salt (Tetramyristoyl cardiolipin)
Figure imgf000020_0002
Ri, R2 = myristoyl (C14:0 chain) [0063] A solution of protected cardiolipin from 1 A (2.5 g, 1.65 mmol) in tetrahydrofuran (40 mL) was hydrogenated at 50 psi over 10% Pd C (900 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 4 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25μ filter and precipitated with acetone to give tetramyristoyl (Cj-j.-o) cardiolipin (1.75 g, 83%) as a white solid. TLC (SiO2) CHCl3/MeOH/NH4OH (6.5:2.5:0.5) Rf~ 0.50.1H NMR δ (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 80H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 3.06(bs, 1H), 3.82-3.98 ( , 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m/z 1240.2 (M-2NH4 ++H+), 1011.9 (M-2NH - RCOO-), 619.9 (M-2NH )2-.
Example 2 Synthesis of Tetralauroyl Cardiolipin
2A. 2-Benzyl-L3- bis [(L2-dilauroyl- «-glycero-3 -ρhosphoryl]glvcerol dibenzyl ester
Figure imgf000021_0001
Rl5 R2 = lauroyl (Cι2:o chain)
[0064] Method 1 : A solution of 1 ,2-dilauroyl-- -glycerol (2.2 g, 4.82 mmol), benzyl N N-tetraisopropyl phosphoramidite (1.95 g, 5.78 mmol) and lH-tetrazole (12.84 mL of 0.45 M sol in acetonitrile, 5.78 mmol) in CH2C12 (25 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (352 mg, 1.92 mmol) in CH2C12 (10 mL) was added followed bylH- tetiazole (12.84 mL of 0.45 M sol in acetonitrile, 5.78 mmol) and stirred for 3 h. The reaction mixture was cooled to -40°C and 3- Chloroperoxyperbenzoic acid (m-CPBA, 2.77 g, 9.64 mmol) was added in portions. After stirring at — 40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CH2CI2 (150 mL), washed {saturated aq Νa2SO3 (2 x 50 mL), saturated aq NaHCO3 (2 x 50 mL), brine (2 x 50 mL)} dried (Na SO ) and concentrated. The residue was purified on SiO2 column (2:3 EtOAc: hexane) to give 1.68 g (62%) of protected cardiolipin as colorless syrup. TLC (SiO2) hexane/EtOAc (3:2) Rf~ 0.44.1H NMR δ (CDCI3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 ( , 64H), 1.52-1.66 (m, 8H), 2.22- 2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, 10H), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H). [0065] Method 2: To a stirred solution of 1,2-Dilauroyl-rø-glycerol (5.0 g, 10.96 mmol) and tetrazole (29.2 mL of 0.45 M sol in acetonitrile, 13.15 mmol) in 40 mL anhydrous CH2CI2, dibenzyl diisopropyl phosphoramidite (4.54g, 13.15 mmol) was added and stirred at room temperature for 2 h. The contents were diluted withlOO mL of CH2C12 and then washed with 5% aqueous NaHCO3 (2 x 50 mL), brine (2 x 50mL), dried over Na2SO4, concentrated in vacuo and the oily residue (7.68 g) was dried in a desiccator for 8 h and used as such in the next reaction. A solution of this phosphite, 2-benzyloxy-l, 3- propanediol (0.8 g, 4.38 mmol), pyridine (4.43 mL, 54.77 mmol) and Et3N (7.63 mL, 54.77 mmol) in CH2CI2 (40 mL) was cooled to - 0°C and pyridinium tribromide (5.25 g, 16.42 mmol) was added at a time. The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were diluted with EtOAc (150 mL) and the organic layer was washed successively with aqueous 5% NaHCO3 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2SO ) and concentrated. The residue was purified on Siθ2 column (8% acetone in CH2CI2) to give 3.8 g (62%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (3:2) Rf~ 0.44.
2B. 1.3- bis [(1.2-dilauroyl-5,n-glycero-3 -phosphoryl]glycerol diammonium salt (Tetralauroyl cardiolipin
Figure imgf000022_0001
Ri, R2 = lauroyl (C^o chain)
[0066] A solution of protected cardiolipin from 2 A (1.5 g, 1.07 mmol) in tetiahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHC13, filtered through a 0.25μ filter and precipitated with acetone to give tetralauroyl (C12:o) cardiolipin (1.0 g, 80%) as a white solid. TLC (SiO ) CHCl3/MeOH/NH4OH (6.5:2.5:0.5) Rf~ 0.48. 1H NMR δ (CDCI3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 64H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 2.94 (bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). 13C NMR δ (CDC13, 125 MHz) 14.07, 22.67, 24.87, 24.93, 29.18, 29.22, 29.36, 29.37, 29.40, 29.57, 29.60, 29.66, 29.67, 29.69, 29.72, 31.91, 34.09, 34.28, 62.62, 63.57, 66.77, 69.47, 70.29, 173.25, 173.56. FTIR (ATR) 3207, 3035, 2956, 2918, 2850, 1737, 1467, 1378,1206,1092, 1067 cm-1. ESI-MS (negative), m/z 1150 (M- 2NH4 ++Na+), 1127.4 (M-2NH 1128.4 (M^NH^+H1"), 928.4 (M-2NH +-RCOO_). 563.7 (M-2NH +)2\ Anal. Calculated for C57H116N2O17P2: C, 58.84; H, 10.05; N, 2.41: P, 5.32. Found: C, 57.75; H, 9.83; N, 2.34: P, 5.28.
Example 3 Synthesis of Tetralauroyl Cardiolipin
[0067] In this method the tetralauroyl cardiolipin was synthesized by 2-cyanoethyl phosphoramidite.
3A. 2-Benzyl-1.3- bis [(L2-dilauroyl- ^-glvcero-3Vphosphoryl]glycerol dicyanoethyl ester
Figure imgf000023_0001
Ri, R2 = lauroyl (C12:o chain)
[0068] To a mixture of 1,2-dilauroyl-^-glycerol (1.74 g, 3.79 mmol) andN, N- diisopropyle hylamine (545 mg, 4.22 mmol) in anhydrous ether (20 mL) under argon atmosphere was added 2-cyanoethyl diisopropylchlorophosphoramidite (1 g, 4.22mmol). The mixture was stirred at room temperature for lh, the separated disiopropylamine hydrochloride was filtered, and the filtrate was concentrated in vacuo. The residue was as such used for the phosphorylation.
[0069] To a mixture of above phosphoramidite and lH-tetrazole (9.4 mL of 0.45 M sol in acetonotrile, 4.22 mmol) in anhydrous CH2C12 (30 mL) was added a solution of 2- benzyloxy 1,3-propanediol (312 mg, 1.71 mmol) in CH2C12 (5 mL). The reaction mixture was stirred at room temperature for 3 h and cooled to -40°C and m-CPBA (1.36 g, 4.73 mmol was added in portions. After stirring at - 0°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CH2C12 (200 mL), washed {saturated aq Νa2SO3 (2 x 50 mL), saturated aq NaHCO3 (2 x 50 mL), brine (2 x 50 mL)} dried (Na2SO4) and concentrated. The residue was purified on Siθ2 column (1 :4 acetone: CH2CI2) to give 1.48 g (70%) as colorless syrup. TLC (SiO2) EtOAc/ CH2C12 (1:3) Rf~ 0.48.1H NMR δ (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 64H), 1.53-1.66 (m, 8H), 2.26- 2.36 (m, 8H), 2.64-2.75 (m, 4H), 3.83-3.88 (m, 1H), 4.06-4.36 (m, 16H), 4.67 (s, 2H), 5.19- 5.28 (m, 2H), 7.28-7.38 (m, 5H).
3B. 1.3- bis [(L2-dilauroyl- -glycero-3Vphosphoryl]-2-benzylglvcerol diammonium salt
Figure imgf000024_0001
Ri, R2 = lauroyl (C^o chain)
A solution of the precursor from 3A (1.48 g, 1.2 mmol) and Et3N (1.66 mL, 12 mmol) in 10 mL acetonitrile was stirred overnight (TLC showed no remaining starting material) and evaporated to dryness. The residue was converted into ammonium salt by adding 2 mL of NH4OH and purified on SiO2 column (15% MeOH in CH2C12 containing 1% NH4OH) to give 850 mg (60%) as colorless syrup that slowly solidifιed.xH NMR δ (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 64H), 1.53-1.63 (m, 8H), 2.22-2.34 (m, 8H), 3.66- 3.76 (m, 1H), 3.82- 4.06 (m, 8H), 4.08-4.18 (m, 2H), 4.26- 4.37 (m, 2H), 4.60 (s, 2H), 5.14- 5.26 (m, 2H), 7.22-7.36 ( , 5H), 7.49 (bs, 8H).
3C. 1.3- bis [f L2-dilauroyl-sn-glycero-3>phosphoryl]glycerol diammonium salt (Tetralauroyl cardiolipin)
Figure imgf000024_0002
Ri, R2 = lauroyl (C12:o chain)
[0070] A solution of protected cardiolipin from 3B (1.12 g, 0.89 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (450 mg) for 10 h. The catalyst was filtered off over celite bed and concentrated, the residue was dissolved in CHCI3, filtered through a 0.25 μ filter and precipitated with acetone to give tetralauroyl (Ci2:o) cardiolipin (750 mg, 75%) cardiolipin as a white solid. TLC (SiO2) column CHCk/MeOH/NPLOH (6.5:2.5:0.5) Rf~ 0.48. The tetralauroyl cardiolipin prepared by this method described herein is identical to that of 2B in all aspects.
Example 4 Synthesis of Tetradecanoyl Cardiolipin
4 A. Synthesis of L2-Didecanoyl-3 -benzyl-^- glycerol
Figure imgf000025_0001
Ri, R2 = decanoyl ( oio chain)
[0071] To an ice cooled solution of (R)-(+)-3-benzyloxy-l, 2-propanediol (2.0 g, 10.97 mmol) and Et3N (6.89 mL, 49.36 mmol) in CH2CI2 (30 mL) was added decanoyl chloride (5.1 mL, 24.69 mmol) dropwise over a period of 10 minutes followed by 4- (Dimethylamino)pyridine (DMAP, 268 mg, 2.19 mmol). The reaction mixture was stirred at room temperature for 12 h, diluted with CH2CI2 (200 mL) washed successively with water (100 mL) and brine (100 mL), dried (Na2SO ) and concentrated. The residue was purified on Siθ2 column (3% EtOAc in hexane) to give 4.5 g (83%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (9:1) Rf ~ 0.54. 1H NMR δ (CDCI3, 300 MHz) 0.87 (t, J = 7.0 Hz, 6H), 1.22-1.34 (m, 24H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J = 4.2 Hz, 2H), 4.18 (dd, J = 6.4 and 11.9 Hz, 1H), 4.34 (dd, J = 6.4 and 11.9 Hz, 1H), 4.51 (d, J = 12.2 Hz, 1H), 4.57 (d, J = 12.2 Hz, 1H), 5.21-5.28 (m, 1H), 7.28-7.36 (m, 5H).
4B. 1.2-Didecanoyl-,S7.-grycerol
Figure imgf000025_0002
Ri, R2 = decanoyl (C^o chain)
[0072] A solution of protected didecanoylglycerol from 4A (4.68 g, 9.55 mmol) in EtOH: EtOAc: AcOH (9:1:0.1) (40 mL) was hydrogenated at 40 psi over 10% Pd/C (600 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated; the resulting DDG (3.52g, 92%) was dried under high vacuum. TLC (SiO2) hexane/EtOAc (3:2) Rf ~ 0.39.1H NMR δ (CDC13, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 24H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, 1H, D2O exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2.35 (t, J= 7.6 Hz, 2H) 3.73 (t, J= 6.0 Hz, 2H)), 4.22 (dd, J= 5.8 and 11.9 Hz, 1H), 4.33 (dd, J= 5.8 and 11.9 Hz, 1H), 5.08 (quintet, J= 5.1 Hz, 1H).
4C. 2-Benzyl-L3- bis [fl.2-didecanoyl-,s7.-glycero-3)-phosphoryl]glycerol dibenzyl ester
Figure imgf000026_0001
Ri, R2 = decanoyl ( oro chain)
[0073] A solution of 1 ,2-didecanoyl-.src-glycerol from 4B (3.52 g, 8.8 mmol), benzyl N, N-tetraisopropyl phosphoramidite (3.26 g, 9.68 mmol) and IH-tetiazole (21.51 mL of 0.45 M sol in acetonitrile, 9.68 mmol) in CH2CI2 (25 mL) was stirred at room temperature under argon for 3 h. A solution of 2-benzyloxy 1,3-propanediol (712 mg, 3.9 mmol) in CH2CI2 * (10 mL) was added followed by 1H- tetrazole (21.51 mL of 0.45 M sol in acetonitrile, 9.68 mmol) and stirred for 3 h. The reaction mixture was cooled to -40°C and m-CPBA (5.06 g, 17.6 mmol) was added in portions. After stirring at -40°C for 30 minutes, the reaction mixture was warmed to room temperature, diluted with CH2CI2 (200 mL), washed {saturated aq Νa2SO3 (2 x 50 mL), saturated aq NaHCO3 (2 x 50 mL), brine (2 x 50 mL)} dried (Na2SO4) and concentrated. The residue was purified on SiO2 column (2:3 EtOAc: hexane) to give 3.2 lg (64%) of protected cardiolipin as colorless syrup. TLC (SiO2) hexane/EtOAc (3:2) Rf~ 0.44.1H NMR δ (CDCI3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H),
1.22-1.34 (m, 48H), 1.52-1.66 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, 1H), 4.01-4.16 (m, 10H), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28-7.36 (m, 15H). 4D. 1,3- bis [(L2-didecanoyl-sκ-glycero-3)-phosphoryl]glvcerol diammonium salt
Figure imgf000027_0001
Ri, R2 = decanoyl (Cιo:o chain)
[0074] A solution of protected cardiolipin from 4C (1.5 g, 1.16 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHC13, filtered through a 0.25μ filter and concentrated to give tetradecanoyl (Cio-.o) cardiolipin (1.0 g, 80%) as a semi solid. TLC (SiO2) CHCl3/MeOH/NH4OH (6.5:2.5:0.5) Rf ~ 0.42.1H NMR δ (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (br s, 48H), 1.52-1.66 (m, 8H), 2.26-2.34 (m, 8H), 3.62 (bs, 1H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m/z 1038 (M-2NH ++Na+), 1015 (M-2NH ), 843.7 (M-2NH4 +- RCOO"), 507.5 (M-2NH4 +)2\
Example 5
Synthesis of Tetraoctanoyl Cardiolipin
5A. L2-Dioctanoyl-3-benzyl- -glycerol
Figure imgf000027_0002
Ri, R2 = octanoyl (C8:o chain)
[0075] To a solution of (R)-(+)-3-benzyloxy-l, 2-propanediol (4.0g, 21.95 mmol) in anhydrous pyridine (40 mL) was added octanoyl chloride (8.93 g, 54.87 mmol) dropwise over a period of 10 minutes followed by DMAP (267 mg, 2.19 mmol). The reaction mixture was stirred at 55°C for 48 h, diluted with EtOAc (300 mL) washed successively with water (100 mL), IN HCl (2 x 100 mL) and brine (100 mL), dried (Na2SO4) and concentrated. The residue was purified on SiO2 column (3% EtOAc in hexane) to give 7.3 g (75%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (9:1) R ~ 0.52.1H NMR δ (CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.66 (m, 4H), 2.22-2.34 (m, 4H), 3.58 (d, J= 4.2 Hz, 2H), 4.18 (dd, J= 6.A and 11.9 Hz, IH), 4.34 (dd, J= 6.4 and 11.9 Hz, IH), 4.51 (d, J= 12.2 Hz, IH), 4.57 (d, J= 12.2 Hz, IH), 5.21-5.28 (m, IH), 7.28-7.36 (m, 5H).
5B. L2-Dioctanoyl-,S77-glycerol
Figure imgf000028_0001
Ri, R2 = octanoyl (C8:o chain)
[0076] A solution of protected dioctanoyl glycerol from 5A (6.8 g, 15.66mmol) in EtOH: EtOAc: AcOH (9:1:0.1) (30 mL) was hydrogenated at 40 psi over 10% Pd/C (900 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated; the resulting DOG (5.0, 93%) was dried under high vacuum. TLC (SiO2) hexane/EtOAc (3 :2) Rf ~ 0.31.1H NMR δ (CDCI3. 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52- 1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, IH, D2O exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2.35 (t, J = 7.6 Hz, 2H) 3.73 (t, J= 6.0 Hz, 2H))', 4.22 (dd, J= 5.8 and 11.9 Hz, IH), 4.33 (dd, J= 5.8 and 11.9 Hz, IH), 5.08 (quintet, J= 5.1 Hz, IH).
5C. 2-Benzyl-l. 3- bis [(L2-dioctanoyl-s/.-glycero-3)-phosphoryl]glycerol dibenzylester
Figure imgf000028_0002
Rl5 R2 = octanoyl (C8:o chain) [0077] To a solution of l,2-Dioctanoyl-,s'«-glycerol from 5B (5.0 g, 14.53 mmol) and tetrazole (40.3 mL of 0.45 M sol in acetonitrile, 18.16 mmol) in 50 mL anhydrous CH2C12, dibenzyl diisopropyl phosphoramidite (6.26g, 18.16 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with 200 mL of EtOAc and then washed with 5% aqueous NaHCO3 (2 x 50 mL), brine (2 x 50mL), dried over Na2SO , concentrated in vacuo and the oily residue (7.0 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0078] A solution of above phosphite, 2-benzyloxy-l, 3-propanediol (0.660 g, 3.63 mmol), pyridine (10.6 mL, 131.13 mmol) and Et3N (8.0 mL, 65.65 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (6.3 g, 19.69 mmol) was added at a time. The mixture was stirred at the same temperature for 1 h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were diluted with EtOAc (250 mL) and the organic layer was washed successively with aqueous 5% NaHCO3 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2SO ) and concentrated. The residue was purified on SiO2 column (10% acetone in CH2C12) to give 2.72 g (64%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (3:2) Rf ~ 0.44. *H NMR δ (CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 0.89 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 32H), 1.52-1.62 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, IH), 4.01-4.16 (m, 10H), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28- 7.36 (m, 15H).
5D. 1.3- bis [π.2-dioctanoyl- -glycero-3Vphosphoryl]-2-berιzyl glycerol diammonium salt
Figure imgf000029_0001
Ri, R2 = octanoyl (C8:o chain)
[0079] A solution of protected cardiolipin from 5C (2.5 g, 2.12 mmol) in 2-butanone (15 mL) and sodium iodide (956 mg, 6.36 mmol) was refluxed at 90°C for 3 h. The volatiles were evaporated and the residue was purified on SiO2 column (20% methanol in CH2CI2 containing 1% of ammonia) to give 1.52 g (75%) of the product as colorless semisolid. TLC (SiO2) CHCls/MeOH/NttfOH (6.5:2.5:0.5) Rf~ 0.53. 1H NMR δ (CDCI3, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 32H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.66-3.76 (m, IH), 3.82- 4.06 (m, 8H), 4.08-4.18 (m, 2H), 4.26- 4.37 (m, 2H), 4.60 (s, 2H), 5.14-5.26 ( , 2H), 7.22-7.36 (m, 5H), 7.49 (bs, 8H). 5E. 1.3- bis ffl.2-dioctanoyl--?7--glvcero-3>phosphoryl]glycerol diammonium salt
Figure imgf000030_0001
Ri, R2 = octanoyl (C8:o chain)
[0080] A solution of protected cardiolipin from 5D (1.5 g, 1.27 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHC13, filtered through a 0.25μ filter and concentrated to give C8 cardiolipin (950 mg, 80%) as a semi solid. TLC (SiO2) CHCl3/MeOH/NH4OH (6.5:2.5:0.5) Rf~ 0.43.1H NMR δ (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 32H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m z 925.7 (M-2NH ++Na+)-, 903.1(M-2NH +), 760.6 (M-2NH4 +-RCOO_), 451.2 (M-2NH4 +)2\
Example 6
Synthesis of Tetrahexanoyl Cardiolipin
6A. 1.2-Dihexanoyl-3-benzyl-,s73-glycerol
Figure imgf000030_0002
Ri, R2 = hexanoyl (C6:o chain)
[0081] To a solution of (R)-(+)-3-benzyloxy-l, 2-propanediol (2.6 g, 14.26 mmol) in anhydrous pyridine (30 mL) was added hexanoyl chloride (4.8 g, 35.67 mmol) dropwise over a period of 10 minutes followed by DMAP (175 mg, 1.42 mmol). The reaction mixture was stirred at 55°C for 48 h, diluted with EtOAc (200 mL) washed successively with water (100 mL), IN HCl (2 x 100 mL) and brine (100 mL), dried (Na2SO4) and concentrated. The residue was purified on SiO2 column (3% EtOAc in hexane) to give 4.1 g (76%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (9:1) Rf ~ 0.48.1H NMR δ (CDC13, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 8H), 1.52-1.66 (m, AH), 2.22-2.34 (m, 4H), 3.58 (d, J= 4.2 Hz, 2H), 4.18 (dd, J= 6.A and 11.9 Hz, IH), 4.34 (dd, J= 6.4 and 11.9 Hz, IH), 4.51 (d, J= 12.2 Hz, IH), 4.57 (d, J= 12.2 Hz, IH), 5.21-5.28 (m, IH), 7.28-7.36 (m, 5H).
6B. 1.2-Dihexanoyl-,s7?-grycerol
Figure imgf000031_0001
Ri, R2 = hexanoyl (C6:o chain)
[0082] A solution of protected dihexanoylglycerol from 6A (3.1 g, 8.2 mmol) in EtOH: EtOAc: AcOH (9:1 :0.1) (30 mL) was hydrogenated at 40 psi over 10% Pd/C (600 mg, 10%) for 3 h. The catalyst was filtered off over celite bed and concentrated; the resulting glycerol (3.52g, 92%) was dried under high vacuum. TLC (Siθ2) hexane EtOAc (3:2) Rf ~ 0.34.1H NMR δ (CDC13, 300 MHz) 0.87 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 8H), 1.52-1.66 (m, 4H), 2.03 (t, J= 6.2 Hz, IH, D2O exchangeable), 2.32 (t, J= 7.6 Hz, 2H), 2.35 (t, J= 7.6 Hz, 2H) 3.73 (t, J= 6.0 Hz, 2H)), 4.22 (dd, J= 5.8 and 11.9 Hz, IH), 4.33 (dd, J= 5.8 and 11.9 Hz, IH), 5.08 (quintet, J= 5.1 Hz, IH).
6C. 2-Benzyl-l. 3- bis [(1.2-dihexanoyl-s -glycero-3)-phosphoryl] glycerol dibenzyl ester
Figure imgf000031_0002
Ri, R2 = hexanoyl (C6:o chain)
[0083] To a solution of l,2-Dihexanoyl--f«-glycerol from 6B (3.5g, 13.19 mmol) and tetrazole (35.1 mL of 0.45 M sol in acetonitrile, 15.83 mmol) in 40 mL anhydrous CH2C ., dibenzyl diisopropyl phosphoramidite (5.46g, 15.83 mmol) was added and stirred at room temperature for 2 h. The contents were diluted with 200 mL of CH2C12 and then washed with 5% aqueous NaHCO3 (2 x 50 mL), brine (2 x 50mL), dried over Na2SO4, concentrated in vacuo and the oily residue (7.0 g) was dried in a desiccator for 8 h and used as such in the next reaction.
[0084] A solution of above phosphite, 2-benzyloxy-l, 3-propanediol (0.957 g, 5.25 mmol), pyridine (10.6 mL, 131.13 mmol) and Et3N (8.0 mL, 65.65 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (6.3 g, 19.69 mmol) was added at a time. The mixture was stirred at the same temperature for 1 h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were diluted with EtOAc (250 mL) and the organic layer was washed successively with aqueous 5% NaHCO3 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2SO ) and concentrated. The residue was purified on Siθ2 column (10% acetone in CH2CI2) to give 3.57 g (64%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (3:2) Rf ~ 0.40. 1H NMR δ (CDCI3, 500 MHz) 0.87 (t, J= 7.0 Hz, 6H), 0.89 (t, J= 7.0 Hz, 6H), 1.22-1.34 (m, 16H), 1.52-1.62 (m, 8H), 2.22-2.29 (m, 8H), 3.70-3.78 (m, IH), 4.01-4.16 (m, 10H), 4.22-4.28 (m, 2H), 4.60 (d, J= 7.8 Hz, 2H), 5.01-5.05 (m, 4H), 5.15-5.18 (m, 2H), 7.28- 7.36 (m, 15H).
6D. 1.3- bis [f L2-dihexanoyl-572-glvcero-3Vphosphoryl] glycerol diammonium salt
Figure imgf000032_0001
Ri, R2 = hexanoyl (C6:o chain)
[0085] A solution of protected cardiolipin from 6C (1.5 g, 1.41 mmol) in tetrahydrofuran (25 mL) was hydrogenated at 50 psi over 10% Pd/C (600 mg) for 10 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated. The residue was dissolved in CHCI3, filtered through a 0.25μ filter and concentrated to give C6 cardiolipin (940 mg, 81%) as a semi solid. TLC (SiO2) CHCl3/MeOH/NH4OH (6.5:2.5:0.5) Rf~ 0.36.1H NMR δ (CDCI3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 16H), 1.56-1.64 (m, 8H), 2.22-2.34 (m, 8H), 3.82-3.98 (m, 9H), 4.12-4.18 (m, 2H), 4.35-4.42 (m, 2H), 5.14-5.24 (m, 2H), 7.41 (bs, 8H). ESI-MS (negative), m/z 813 (M-2NH ++Na+), 791 (M-2NH4 ++H+), 395 (M-2NH )2". Example 7 Synthesis of Tetraoleoyl Cardiolipin (unsaturated)
7 A. C..y-5-Levulinoy 1-2-phenyl- 1.3 -dioxane
Figure imgf000033_0001
[0086] To a solution of cis-l,3-O-benzylideneglycerol (5.0 g, 27.74 mmol) in CH2C12 (80 mL) at 0°C, DCC (8.58 g, 41.61 mmol), DMAP (3.38 g, 27.74) and levulinic acid (4.0 g, 34.68 mmol) were sequentially added. The mixture was stirred for 24 hrs at room temperature. The separated urea was filtered, the filtrate was concentrated and purified by flash chromatography with 80% EtOAc/hexane as eluent to afford the product as a white solid (5.86 g, 76%). TLC (SiO2) hexane/EtOAc (1:1) Rf ~ 0.51^ NMR δ (CDC13, 300 MHz) 2.19 (s, 3H), 2.58-2.89 (m, 4H), 4.18 (dd, J= 12.0, 1.5 Hz, 2H), 4.25 (dd, J= 12.0, 1.5 Hz, 2H), 4.71 (dd, J= 1.5, 1.5 Hz, IH), 5.55 (s, IH), 7.24-7.53 (m, 5H).
7B. 2-Levulinoyl-1.3-propanediol
Figure imgf000033_0002
[0087] A solution of protected glycerol 7A (5.8 g, 20.86 mmol) in EtOH: EtOAc (1:1) (100 mL) was hydrogenated at 50 psi over 10% Pd/C (800 mg, 10%) for 8 h. The catalyst was filtered off over celite bed and concentrated; the resulting 2-levulinoyl glycerol was purified by flash chromatography with 6% MeOH/CH2Cl2 as eluent to afford the product as a white solid (2.82 g, 70%). TLC (SiO2) MeOH/CH2Cl2 (1:9) Rf ~ 0.31.1H NMR δ (CDC13, 300 MHz) 2.19 (s, 3H), 2.58 (dd, J= 6.0, 6.0 Hz, 2H), 2.80 (dd, J= 6.0, 6.0 Hz, 2H), 3.09 (bs, 2H), 3.72-3.87 (m, 4H), 4.90 (q, J= 5.1 Hz). 7C. 2-Levulinoyl-L3- bis [fl.2-dioleoyl- -glycero-3)-phosphoryl]glycerol dibenzyl ester
Figure imgf000034_0001
Ri, R2 = oleoyl (Cig-.i
Figure imgf000034_0002
[0088] To a solution of l,2-Dioleoyl-5«-glycerol (1.5g, 2.41 mmol) and tetrazole (8 mL of 0.45 M sol in acetonitrile, 3.62 mmol) in 20 mL anhydrous CH2C12, dibenzyl diisopropyl phosphoramidite (1.25g, 3.62 mmol) was added and stirred at room temperature for 2 h. The contents were diluted withlOO mL of CH2C12 and then washed with 5% aqueous NaHCO3 (2 x 50 mL), brine (2 x 50mL), dried over Na2SO , concentrated in vacuo and the oily residue (2.08 g) was dried in a desiccator for 8 h and used as such in the next reaction. [0089] A solution of above phosphite, 2-levulinoyl- 1 , 3 -propanediol from 7B (0.185 g, 0.96 mmol), pyridine (2 mL, 24.1 mmol) and Et3N (1.2 mL, 12.05 mmol) in CH2C12 (20 mL) was cooled to -40°C and pyridinium tribromide (1.15 g, 3.61 mmol) was added at a time. The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (10 mL) . The contents were diluted with EtOAc (100 mL) and the organic layer was washed successively with aqueous 5% NaHCO3 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2SO4) and concentrated. The residue was purified on Siθ2 column (5% acetone in CH2CI2) to give 1.09 g (66%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (1:2) Rf ~ 0.64. 1H NMR δ (CDCI3, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 80H), 1.52-1.66 (m, 8H), 1.96-2.07 (m, 16H), 2.15 (s, 3H), 2.22-2.31 (m, 8H), 2.52-2.57 (m, 2H), 2.66-2.74 (m, 2H), 4.01-4.32 (m, 12H), 5.01-5.10 (m, 5H), 5.15-5.18 (m, 2H), 5.28-5.39 (m, 8H), 7.28- 7.39 (m, 10H). 7D. 1.3- bis i.2-dioleoyl- ,^-glycero-3)-phosphoryl]-2-levulinoyl glycerol diammonium salt
Figure imgf000035_0001
Ri, R2 = oleoyl (C18:1 chain)
[0090] A solution of protected cardiolipin from 7C (0.525 g, 0.324 mmol) in 2- butanone (8 mL) and sodium iodide (145 mg, 0.972 mmol) was refluxed at 90°C for 3 h. The volatiles were evaporated and the residue was purified on Siθ2 column (10% methanol in CH2CI2 containing 1% of ammonia) to give 240 mg (50%) of the product as colorless semisolid. TLC (SiO2) CHCl3/MeOH NH OH (6.5:2.5:0.5) Rf~ 0.63.1H NMR δ (CDC13, 300 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 80H), 1.52-1.65 (m, 8H), 1.96-2.07 (m, 16H), 2.18 (s, 3H), 2.23-2.35 (m, 8H), 2.52-2.59 (m, 2H), 2.71-2.79 (m, 2H), 3.83-4.04 (m, 6H), 4.12-4.23 (m, 4H), 4.31-4.39 (m, 2H), 5.01-5.09 (m, IH), 5.17-5.26(m, 2H), 5.28-5.39 (m, 8H), 7.41-7.59 (bs, 8H). ESI-MS (negative), m/z 1576.5 (M-2NH4 ++Na+T, 1554 (M- 2NEU+), 1272.2 (M-2NH -RCOO-), 776 (M-2NH )2".
7E. 1.3- bis [fl,2-dioleoyl-5w-glycero-3Vphosphoryl] glycerol diammonium salt (Synthesis of Tetraoleoyl Cardiolipin)
Figure imgf000035_0002
Ri, R2 = oleoyl (Cisu chain)
[0091] To a solution of lev- protected cardiolipin from 7D (140 mg, 0.088 mmol) in pyridine:acetic acid (3 mL, 4:1) was added hydazine (14 mg, 0.44 mmol) and stirred for 30 minutes. The volatiles were removed in rotavapor and the residue was purified on Siθ2 (10% methanol in CH2CI2 containing 1% of ammonia) to give 80 mg (61%) of the product as colorless semisolid. TLC (SiO2) (6.5:2.5:0.5) Rf~ 0.55. 1H NMR δ (CDCI3, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.39 (m, 80H), 1.52-1.65 (m, 8H), 1.82 (bs, IH), 1.96-2.07 (m, 16H), 2.23-2.35 (m, 8H), 3.83-3.94 (m, 7H), 4.12-4.23 (m, 4H), 4.33-4.39 (m, 2H), 5.17-5.23 (m, 2H), 5.28-5.39 (m, 8H), 7.41-7.59 (bs, 8H). ESI-MS (negative), m/z 1478 (M-2NH4 +-HNa )\ 1456 (M-2NTV), 1174.2 (M-2NH4 +-RCOO"), 727.5 (M-2NH4 +)2".
Cardiolipin Ether Analogs
Example 8
Synthesis of Tetralauryl eardiolipin
8A. 2-Benzyl-l,3- bis [(1.2-dilauryl- -glycero-3)-phosphoryl]glycerol dibenzyl ester
Figure imgf000036_0001
Ri, R2 = lauryl (Cι2:o chain)
[0092] To a stirred solution of l,2-Dilauryl-5«-glycerol (3.0 g, 7.00 mmol) and tetrazole (19.5 mL of 0.45 M sol in acetonitrile, 8.76 mmol) in 40 mL anhydrous CH2C12, dibenzyl diisopropyl phosphoramidite (3.02g, 8.76 mmol) was added and stirred at room temperature for 2 h. The contents were diluted withlOO mL of CH2C12 and then washed with 5% aqueous NaHCO3 (2 x 50 mL), brine (2 x 50mL), dried over Na2SO4, concentrated in vacuo and the oily residue (4.5 g) was dried in a desiccator for 8 h and used as such in the next step reaction. [0093] A solution of above phosphite, 2-benzyloxy-l, 3-propanediol (0.48 g, 2.67 mmol), pyridine (5.43 mL, 66.8 mmol) and Et3N (4.63 mL, 33.4 mmol) in CH2C12 (40 mL) was cooled to -40°C and pyridinium tribromide (3.25 g, 10.02 mmol) was added at a time. The mixture was stirred at the same temperature forl h and gradually allowed to attain room temperature over a period of 2 h and treated with water (30 mL). The contents were diluted with EtOAc (150 mL) and the organic layer was washed successively with aqueous 5% NaHCO3 (2 x 50 mL), water (50 mL) and brine (50 mL), dried (Na2SO4) and concentrated. The residue was purified on SiO2 column (30% ethylacetate in hexane) to give 2.34 g (67%) of the product as colorless syrup. TLC (SiO2) hexane/EtOAc (3:2) Rf ~ 0.47. 1H NMR δ (CDC13, 300 MHz) 0.88 (t, J= 6.6 Hz, 12H), 1.22-1.34 (m, 72H), 1.47- 1.56 (m, 8H), 3.35-3.58 (m, 14H), 3.72-3.78 (m, IH), 3.95-4.18 (m, 8H), 4.59-4.61 (m, 2H), 5.02-5.07 (m, 4H), 7.26-7.34 (m, 15H). 3.6
8B. 1.3- bis π.2-dilauryl--?n-glycero-3Vphosphoryl]glycerol diammonium salt (Tetralauryl Cardiolipin)
Figure imgf000037_0001
Ri, R2 = lauryl (C12:o chain)
[0094] A solution of protected cardiolipin from 8A (650 mg, 0.48 mmol) in tetrahydrofuran (20 mL) was hydrogenated at 50 psi over 10% Pd C (200 mg) for 6 h. The catalyst was filtered off over celite bed, treated with 2 mL of 30% ammonia solution and concentrated, the residue was dissolved in CHCI3, filtered through a 0.25μ filter and precipitated with acetone to give 2 cardiolipin (400 mg, 75%) as a white semisolid. TLC (SiO2) CHCL eOH/NILOH (6.5:2.5:0.5) Rf~ 0.39. 1H NMR δ (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 72H), 1.52-1.66 (m, 8H), 3.39-3.48 (m, 9H), 3.51-3.61 (m, 6H), 3.80-3.96 (m, 8H), 7.31-7.59 (bs, 8H). ESI-MS (negative), m/z 1094.1 (M- 2NH4 ++Na+), 1072.0 (M-2NH4 ++H+), 535.5 (M-2NH4 +)2'.
Example 9 Synthesis of Tetrahexyl Cardiolipin
9A. 2-Benzyl-1.3- bis [(1.2-dihexyl- -glycero-3)-phosphoryl] lycerol dibenzyl ester
Figure imgf000037_0002
Rls R2 = hexyl (C6:o chain)
[0095] The title compound was prepared according to the method described in example 8A. TLC (SiO2) hexane/EtOAc (3:2) Rf ~ 0.39. 1H NMR δ (CDC13, 300 MHz) 0.88 (t, J= 6.6 Hz, 12H), 1.22-1.37 (m, 24H), 1.47-1.58 (m, 8H), 3.34-3.58 (m, 14H), 3.72-3.78 (m, IH), 3.94-4.18 (m, 8H), 4.59-4.61 (m, 2H), 5.02-5.08 (m, 4H), 7.26-7.34 (m, 15H). 9B. 1.3- bis [π.2-dihexyl- -glycero-3>phosphoryι] lycerol diammonium salt (Tetrahexyl Cardiolipin)
Figure imgf000038_0001
Ri, R2 = hexyl (C6:o chain)
[0096] The title compound was prepared according to the method described in example 8B.TLC (SiO2) CHCL eOH/NILOH (6.5:2.5:0.5) Rf~ 0.31. 1H NMR δ (CDC13, 500 MHz) 0.88 (t, J= 7.0 Hz, 12H), 1.22-1.34 (m, 24H), 1.50-1.61 (m, 8H), 1.88 (bs, IH), 3.39- 3.48 (m, 9H), 3.51-3.61 (m, 6H), 3.80-3.96 (m, 8H), 7.31-7.69 (bs, 8H).
Example 10 [0097] This example demonstrates preparation of a cardiolipin-containing liposome composition of the invention. Small unilamellar vesicles are formed by mixing 19.1 μmole of cardiolipin, produced according to the methods described herein, 96.2 μmol of phosphatidyl choline and 64.6 μmol of cholesterol. After thorough stirring, the mixture is evaporated to dryness in a 50 ml round-bottom flask using a rotary evaporator. The subsequent dried lipid film is resuspended in 10 ml sterile non-pyrogenic water. After a 30 minute swelling time, the resulting suspension is sonicated in a fixed temperature bath at 25 °C for 15 minutes. The preparation of liposomes is then lyophilized with tiehalose.
[0098] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.
[0099] The use of the terms "a" and "an" and "the" and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms "comprising," "having," "including," and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non- claimed element as essential to the practice of the invention.
[00100] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Nariations of those preferred embodiments might become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
References
1. Drummond, D. C; Meyer, O.; Hong, K.; Kirpotin, D. B.; Papahadgopoulos, D. Pharm. Rev., 1999, 51, 691-743.
2. Ramirez, F.; Ioannou, P. N.; Marecek, J. F.; Golding, B. T.; Dodd, G. H. Synthesis. 1976, 11, 769-770. 3. Duralski, A. A.; Spooner, P. J. R.; Watts, A. Tetrahedron Lett. 1989, 30, 3585-3588.
4. Duralski, A. A.; Spooner, P. J. R.; Rankin, S. E.; Watts, A. Tetrahedron Lett. 1998, 39, 1607-1610.
5. Saunders, R. M.; Schwarz. J. Am. Chem. Soc. 1966, 88, 3844-3847.
6. Mishina, I. M.; Nasilenko, A. E.; Stepanov, A.E.; Shvets, N. I. Bioorg. Khim. 1985, 11, 992-994.
7. Stepanov, A.E.; Makarova, I. JV ; Shvets, N. I. Zh. Org., Khim. 1984, 20, 985-988.
8. DeHaas, G.H.; Bonsen, P.P.M.; NanDeenen, L.L.M. Biochim. Biophys. Acta, 1966, 116: 114-124.
9. Inoue, K.; Suhara, Y.; Νojima, S. Chem. Pharm. Bull, 1963, 1150-1156. 10. Browne, J. E.; Driver, M. J.; Russel, J. C; Sammes, P. G. J. Chem. Soc. Perkin
Trans. 1. 2000, 653-657. 11. Watanabe, Y.; Inada, E.; Jinno, M.; Ozaki, S. Tetrahedron Lett. 1993, 34, 497-500. 12. Watanabe, Y.; Hirofuji, H.; Ozaki, S. Tetrahedron Lett. 1994, 35, 123-124.
13. Watanabe, Y.; Nakamura, T.; Mitsumoto, H. Tetrahedron Lett. 1997, 38, 7407- 7410.
14. Watanabe, Y.; Ishikawa, H. Tetrahedron Lett. 2000, 41, 8509-8512. 15. Watanabe, Y.; Nakatomi, M. Tetrahedron Lett. 1998, 39, 1583-1586.
16. Chen, J.; Feng, L.; Prestwich, G. D. J. Org. Chem. 1998, 63, 6511-6522.
17. Lindberg, J.; Ekeroth, J.; Konradsson, P. J. Org. Chem. 2002, 67, 194-199.
18. Chen, J.; Profit, A. A.; Prestwich, G. D. J. Org. Chem. 1996, 61, 6305-6312.
19. Prestwich, G. D. Ace. Chem. Res. 1996, 29, 503-513. 20. Gu, Q. M.; Prestwich, G. D. J. Org. Chem. 1996, 61, 8642-8647.
21. Murakami, K.; Molitor, E. J.; Liu, H.W. J. Org. Chem. 1999, 64, 648-651.
22. Prestwich, G. D.; Marecek, J. F.; Mourey, R. J.; Thiebert, A.B.; Ferris, C. D.; Danoff, S. K.; Snyder, S. H. J. Am. Chem. Soc. 1991, 113, 1822-1825.
23. Dreef, C. E.; Elie, C. J. J.; Hoogerhout, P.; van der Marel, G. A.; van Boom, J. H. Tetrahedron Lett. 1988, 29, 6513-6516.
24. Inoue, K.; Nojima, S. Chem. Pharm. Bull. 1968, 16, 76-81.
25. Ioannou, P. V.; Marecek, J. F. Chem. Chron. 1986, 15, 205-220.
26. Ramirez, F.; Ioannou, P. V.; Marecek, J. F.; Dodd, G. H.; Golding, B. T. Tetrahedron. 1977, 33, 599-608. 27. Mishina, I. M.; Nasilenko, A. E.; Stepanov, A.E.; Shvets, N. I. Bioorg. Khim. 1987,
75, 1110-1115.
28. Keana, J. F. W.; Shimiju, M.; Jernstedt, K. K. J. Org. Chem. 1986, 51, 2297-2299.
29. Chevallier, J.; Sakai, Ν.; Robert, F.; Kobayashi, T.; Gruenberg, J.; Matile, S. Org. Lett. 2000, 2, 1859-1861. 30. Wilk, A.; Srinivasachar, K.; Beaucage, S. J. Org. Chem. 1997, 62, 6712-6713.
31. Moriguchi, T.; Yanagi, T.; Kunimori, M.; Wada, T.; Sekine, M. J. Org. Chem. 2000, 65, 8229-8238.

Claims

What is claimed is:
A method for preparing a cardiolipin analogue of formulas I, II or III
Figure imgf000041_0001
II
Figure imgf000041_0002
III comprising reacting an alcohol of the formula NIII
Figure imgf000041_0003
NIII with one or more phosphoramide reagents and 2-O-protected glycerol or 2-O-subsituted glycerol in the presence of an acid catalyst, wherein, in Formulas I, II, III, or NIII Yi and Y2 are the same or different and are -Ο-C(Ο)-, -O-, -S-, or -ΝH-C(O)-; Ri and R2 are the same or different and are H, C2to C3 saturated or unsaturated alkyl group; R3 is (CH2)n and n = 0 - 15; Ir is hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, a peptide, dipeptide, polypeptide, protein, carbohydrate, heterocyclic, nucleoside, polynucleotide; R5 is a linker comprising alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkyloxy, polyalkyloxy, a peptide, dipeptide, polypeptide, protein, carbohydrate; X is hydrogen a non-toxic cation.
2. The method of claim 1, wherein the acid catalyst is selected from the group consisting of 4,5-dichloroirnidazole, lH-tetrazole, 5-(4-nitrophenyl)-lH-tetrazole, 5-(3,5-dinitrophenyl)- lH-tetrazole, N-methylimidazolium triflate, and N-methylimidazolium perchlorate, 4,5- dicyanoimidazole, 5-ethylthio-lH-tetrazole, and 5-methylthio-lH-tetrazole.
3. The method of claim 1 or 2 wherein at least one of the coupling phosphoramidites is of formula IV.
Figure imgf000042_0001
IV
4. The method of claim 1 or 2 wherein at least one of the coupling phosphoramidites is of formula V.
Figure imgf000042_0002
V
5. A method for preparing cardiolipin or an analogue thereof of formulas I, II, or III; comprising reacting 2-O protected glycerol with one or more phosphotriesters in the presence of pyridinium tribromide.
6. The method of claim 5, wherein one or more of the phosphotriesters are produced by reacting an alcohol of formula VIII with phosphoramidite of general formula VII.
Figure imgf000042_0003
VII
7. The methods of any of claims 3, 4, or 6, wherein X in formulas IV, V, or VII is a phosphate protecting group including alkyl phosphates including ethyl, cyclohexyl, t-butyl; 2-substituted ethyl phosphates including 2-cyanoethyl, 4-cyano-2-butenyl, 2- (methyldiphenylsilyl)ethyl, 2-(trimethylsilyl)ethyl, 2-(triphenylsilyl)ethyl; haloethyl phosphates including 2,2,2-trichloroethyl, 2,2,2-tiibromoethyl, 2,2,2-trifluoroethyl; benzyl phosphates including 4-chlorobenzyl, fluorenyl-9-methyl, diphenylmethyl and amidates.
8. The method of any of claims 1-7, wherein at least one of Ri and/or R2 is a saturated or unsaturated alkyl group having between 4 and 14 carbons.
9. The method of claims 1-8, wherein the cardiolipin comprises short-chain fatty acids having between 2 and 14 carbons.
10. The method of claim 9, wherein the cardiolipin comprises fatty acids having between 4 and 12 carbons.
11. The method of claims 1-8, wherein the cardiolipin comprises long-chain fatty acids having between 14 and 34 carbons.
12. The method of claim 11 , wherein the cardiolipin comprises fatty acids having between 14 and 24 carbons.
13. The method of claims 1-12, wherein the cardiolipin is saturated and/or unsaturated.
14. A cardiolipin or cardiolipin analogue prepared by the method of any of claims 1-13.
15. A method for preparing a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13 and including the cardiolipin or cardiolipin analogue in a liposome.
16. A method for retaining a drag in a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13, and including the cardiolipin or cardiolipin analogue and a drug in a liposome.
17. A method for retaining drugs in a liposome, comprising preparing a cardiolipin or cardiolipin analogue by the method of claims 1-13, and including the cardiolipin or cardiolipin analogue and a mixture of drugs in a liposome.
18. The method of claim 17, wherein the mixture comprises two or more drugs.
19. A liposomal composition prepared by the method of any of claims 15-18.
20. A lipid composition comprising a cardiolipin or cardiolipin analogue prepared by the method of any of claims 1-13.
21. The composition of claim 20, which is liposomal.
22. The composition of claim 19 or 21, which comprises unilamellar vescicles, multilamellar vesicles, or mixtures thereof.
23. The liposome composition of claim 19 or 21 , wherein the liposomes have a diameter of about 1 micron or less.
24. The liposome composition of claim 19 or 21 , wherein the liposomes have a diameter of about 500 nm or less.
25. The liposome composition of claim 19 or 21, wherein the liposomes have a diameter of about 200 nm or less.
26. The composition of claim 19 or 21 , wherein the liposomes have a diameter of about 100 nm or less.
27. The composition of claim 20, which is other than liposomal.
28. The composition of any of claims 19-27, which further comprises a phosphatidylcholine, a sterol, and a tocopherol.
29. The composition of any of claims 19-28, which further comprises a phosphatidylcholine selected from the group consisting of dimyristoylphosphatidylcholine, distearoylphosphatidylchoHne, dioleylphosphatidylcholine, dipalmitoylphosphatidylcholine, diarachidonoylphosphatidylcholine, egg phosphatidylcholine, soy phosphatidylcholine, hydrogenated soy phosphatidylcholine, and mixtures thereof.
30. The composition of any of claims 19-29, which further comprises a phosphatidylglycerol, selected from the group consisting of dimyristoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, diarachidonoylphosphatidylglycerol, and mixtures thereof.
31. The composition of any of claims 19-30, which further comprises a sterol selected from the group consisting of cholesterol, derivatives of cholesterol, coprostanol, cholestanol, cholestane, cholesterol hemisuccinate, cholesterol sulfate, and mixtures thereof.
32. The composition of any of claims 19-31, comprising one or more targeting agents.
33. The composition of claim 32, wherein the targeting agent is a protein.
34. The composition of claim 33, wherein the protein is selected from groups of proteins consisting of antibodies, antibody fragments, peptides, peptide hormones, receptor ligands, and mixtures thereof.
35. The composition of any of claims 19-34, in lyophilized form.
36. The composition of claim 35, further comprising a cryoprotectant.
37. The composition of any of claims 19-36, further comprising a ligand.
38. The liposome composition of claim 37, wherein the ligand is an antibody or a ligand for a cellular receptor.
39. The composition of any of claims 19-38, which further comprises a pharmaceutically acceptable excipient.
40. The composition of any of claims 18-39, further comprising an active agent.
41. The composition of any of claims 19-40, further comprising a mixture of active agents.
42. The composition of any of claim 41 , wherein said mixture comprises two or more active agents.
43. The composition of any of claims 19-42, wherein at least one of said active agents is complexed with cardiolipin or cardiolipin analogue.
44. The composition of any of claims 19-43, wherein at least one of said active agents is entrapped within liposomes.
45. The use of a composition of any claims 40-44, to prepare a medicament for the treatment of a disease .
46. The use according to claim 45, wherein the disease is cancer.
47. A method of delivering an active agent or mixture of active agents to cell, comprising preparing a composition according to any of the claims 40-44 and exposing the composition to a cell.
48. The method of claim 47, wherein the cell is in vitro.
49. The method of claim 47, wherein the cell is in vivo.
50. A method of treating a human or animal disease, comprising preparing a composition according to any of claims 40-44 and exposing the composition to a human or animal in need thereof such that the active agent is delivered to the human or animal patient.
51. The method of claim 50, wherein the disease is cancer and at least one of said active agents is an anticancer agent.
52. Use of cardiolipin to prepare a medicament to combat aging.
53. Use of cardiolipin to prepare a medicament to combat a mammalian disease.
54. The use according to claim 53, wherein said disease is selected from the group consisting of age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders.
55. The use according to any of claims 52-54, wherein the cardiolipin is in the form of a liposomal composition.
56. The use according to any of claims 52-55, wherein the cardiolipin is other than in the form of a liposomal composition.
57. A method of treating the effects of aging in a patient, comprising administering the patient a therapeutically effective amount of cardiolipin such that the effects of aging are combated in said patient.
58. A method of treating a mammalian disease, comprising administering to a patient in need of treatment an amount of cardiolipin sufficient to treat said disease.
59. The method of claim 58, wherein said disease is selected from the group consisting of age-related diseases, atherosclerosis, diabetes, heart disease, ischemia, and skin disorders.
60. The method of any of claims 57-59, wherein the composition includes, in addition to cardiolipin, one or more pharmaceutically acceptable carriers.
61. The method of any of claims 57-60, wherein the composition is administered dermally.
62. The method of any of claims 57-61, wherein the composition is administered intravenously.
63. The method of any of claims 57-62, wherein the composition is other than a liposomal composition.
PCT/US2003/027806 2002-05-24 2003-09-05 Cardiolipin molecules and method of synthesis WO2004039817A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2005501873A JP2006510733A (en) 2002-10-16 2003-09-05 Cardiolipin molecule and synthesis method
EA200500659A EA200500659A1 (en) 2002-10-16 2003-09-05 Subsidiaries. The process is to get the cardiolipine or its analogue (options) and the contained liposomes.
CA002502285A CA2502285A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
AU2003268478A AU2003268478A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
EP03749443A EP1556392A1 (en) 2002-10-16 2003-09-05 Cardiolipin molecules and method of synthesis
PCT/US2003/033099 WO2004035523A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
EP03809159A EP1558562A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
CA002501990A CA2501990A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
EA200500661A EA200500661A1 (en) 2002-10-16 2003-10-16 CATION ANALOGUE OF CARDIOLIPINE (OPTIONS), ITS APPLICATION (OPTIONS), COMPOSITION AND SET FOR TRANSFECTION OF CELLS (OPTIONS)
AU2003277445A AU2003277445A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof
JP2005501473A JP2006503112A (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogues and uses thereof
US11/105,970 US20050266068A1 (en) 2002-05-24 2005-04-14 Cardiolipin molecules and methods of synthesis
HK05112200.6A HK1080087A1 (en) 2002-10-16 2005-12-30 Cardiolipin molecules and method of synthesis

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US41927702P 2002-10-16 2002-10-16
US60/419,277 2002-10-16
US42928502P 2002-11-26 2002-11-26
US60/429,285 2002-11-26
US43865903P 2003-01-07 2003-01-07
US60/438,659 2003-01-07
US46733103P 2003-05-02 2003-05-02
US60/467,331 2003-05-02
USPCT/US03/13917 2003-05-04
PCT/US2003/013917 WO2004062569A2 (en) 2003-01-07 2003-05-04 Cardiolipin compositions their methods of preparation and use
PCT/US2003/016412 WO2003099830A2 (en) 2002-05-24 2003-05-23 Cardiolipin compositions, methods of preparation and use
USPCT/US03/16412 2003-05-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/105,970 Continuation US20050266068A1 (en) 2002-05-24 2005-04-14 Cardiolipin molecules and methods of synthesis

Publications (2)

Publication Number Publication Date
WO2004039817A1 true WO2004039817A1 (en) 2004-05-13
WO2004039817A9 WO2004039817A9 (en) 2004-07-22

Family

ID=32234368

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/027806 WO2004039817A1 (en) 2002-05-24 2003-09-05 Cardiolipin molecules and method of synthesis
PCT/US2003/033099 WO2004035523A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033099 WO2004035523A1 (en) 2002-10-16 2003-10-16 Cationic cardiolipin analogs and use thereof

Country Status (7)

Country Link
EP (2) EP1556392A1 (en)
JP (2) JP2006510733A (en)
AU (2) AU2003268478A1 (en)
CA (2) CA2502285A1 (en)
EA (2) EA200500659A1 (en)
HK (1) HK1080087A1 (en)
WO (2) WO2004039817A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004935A2 (en) * 2004-06-29 2006-01-12 Neopharm, Inc. Pegylated cardiolipin analogs, methods of synthesis, and uses thereof
WO2006052906A3 (en) * 2004-11-08 2006-08-24 Neopharm Inc Synthesis of cardiolipin analogues and uses thereof
EP1986607A2 (en) * 2006-02-24 2008-11-05 Neopharm, Inc. Method and process for preparing cardiolipin

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
WO2006113679A2 (en) 2005-04-15 2006-10-26 Board Of Regents, The University Of Texas System Delivery of sirna by neutral lipid compositions
WO2007014150A2 (en) * 2005-07-22 2007-02-01 Neopharm, Inc. Method of administering liposomes containing oligonucleotides
WO2007065017A2 (en) * 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Oligonucleotide cationic liposomal delivery system
PL1957044T3 (en) 2005-12-01 2013-11-29 Pronai Therapeutics Inc Amphoteric liposome formulation
DK2344198T3 (en) * 2008-09-27 2020-11-30 Jina Pharmaceuticals Inc LIPID-BASED PHARMACEUTICAL PREPARATIONS FOR TOPIC USE
MX2014012135A (en) * 2012-04-11 2015-07-23 Lipoxen Technologies Ltd Liposomes containing oligopeptide fragments of myelin basic protein, a pharmaceutical composition and a method for treatment of multiple sclerosis.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2113606A (en) * 1934-05-24 1938-04-12 Alba Pharmaceutical Company In Quaternary ammonium compounds
EP1129064B1 (en) * 1998-11-12 2008-01-09 Invitrogen Corporation Transfection reagents
JP4723097B2 (en) * 1999-05-28 2011-07-13 バイカル インコーポレイテッド Cytofectin dimer and method of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461637B1 (en) * 2000-09-01 2002-10-08 Neopharm, Inc. Method of administering liposomal encapsulated taxane

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROWNE J. E. ET AL.: "Preparation of phospholipid analogues using the phosphoramisite route", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1., no. 5, 2000, GBCHEMICAL SOCIETY. LETCHWORTH., pages 653 - 657, XP002270563 *
DURALSKI A A ET AL: "Synthesis of Isotopically Labelled Cardiolipins", TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 39, no. 12, 19 March 1998 (1998-03-19), pages 1607 - 1610, XP004108111, ISSN: 0040-4039 *
GOKHALE PC ET AL: "AN IMPROVED METHOD OF ENCAPSULATION OF DOXORUBICIN IN LIPOSOMES: PHARMACOLOGICAL, TOXIGOLOGICAL AND THERAPEUTIC EVALUATION", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 74, no. 1, July 1996 (1996-07-01), pages 43 - 48, XP000961424, ISSN: 0007-0920 *
INOUE K ET AL: "IMMUNOCHEMICAL STUDIES OF PHOSPHOLIPIDS. II. SYNTHESES OF CARDIOLIPIN AND ITS ANALOGUES", CHEMICAL AND PHARMACEUTICAL BULLETIN, TOKYO, JP, vol. 16, no. 1, 1968, pages 76 - 81, XP000909008, ISSN: 0009-2363 *
MISHINA I M ET AL: "COMPLEX LIPIDS. SYNTHESIS OF A DIPHOSPHATIDYLGLYCEROL (CARDIOLIPIN) WITH UNSATURATED FATTY ACID RESIDUES", 1985, SOVIET JOURNAL OF BIOORGANIC CHMEISTRY, NEW YORK, NY, US, PAGE(S) 593-597, ISSN: 0360-4497, XP009003324 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004935A2 (en) * 2004-06-29 2006-01-12 Neopharm, Inc. Pegylated cardiolipin analogs, methods of synthesis, and uses thereof
WO2006004935A3 (en) * 2004-06-29 2006-06-01 Neopharm Inc Pegylated cardiolipin analogs, methods of synthesis, and uses thereof
WO2006052906A3 (en) * 2004-11-08 2006-08-24 Neopharm Inc Synthesis of cardiolipin analogues and uses thereof
JP2008519058A (en) * 2004-11-08 2008-06-05 ネオファーム、インコーポレイティッド Synthesis of cardiolipin analogues and their use
EP1986607A2 (en) * 2006-02-24 2008-11-05 Neopharm, Inc. Method and process for preparing cardiolipin
EP1986607A4 (en) * 2006-02-24 2010-02-10 Neopharm Inc Method and process for preparing cardiolipin

Also Published As

Publication number Publication date
CA2502285A1 (en) 2004-05-13
WO2004039817A9 (en) 2004-07-22
AU2003268478A1 (en) 2004-05-25
CA2501990A1 (en) 2004-04-29
JP2006503112A (en) 2006-01-26
AU2003277445A1 (en) 2004-05-04
WO2004035523A1 (en) 2004-04-29
WO2004035523B1 (en) 2004-08-26
EA200500659A1 (en) 2005-10-27
HK1080087A1 (en) 2006-04-21
EP1556392A1 (en) 2005-07-27
EA200500661A1 (en) 2005-10-27
JP2006510733A (en) 2006-03-30
EP1558562A1 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
US20050266068A1 (en) Cardiolipin molecules and methods of synthesis
US20050181037A1 (en) Cardiolipin compositions their methods of preparation and use
US20050277611A1 (en) Cationic cardiolipin analoges and its use thereof
US20170210775A1 (en) Guggulphospholipid methods and compositions
EP0702556B1 (en) (phospho)lipids for combatting hepatitis b virus infection
US20080286351A1 (en) Pegylated Cardiolipin Analogs, Methods of Synthesis, and Uses Thereof
US8129552B2 (en) Phospholipids with unsaturated alkyl and acyl chains
EP1556392A1 (en) Cardiolipin molecules and method of synthesis
WO2006029081A2 (en) Nucleoside-lipid conjugates, their method of preparation and uses thereof
US20080300418A1 (en) Synthesis of Cardiolipin Analogues and Uses Thereof
AU754862B2 (en) Use of bisphosphonates for the prevention and treatment of infectious processes
JP2001515082A (en) Phospholipid-like compounds
WO2007100808A2 (en) Method and process for preparing cardiolipin
US11690818B2 (en) Drug containing liver targeting specific ligand and thyroid hormone receptor agonist
CN1714095A (en) Cardiolipin molecules and method of synthesis
WO2004062569A2 (en) Cardiolipin compositions their methods of preparation and use
JP2003522203A (en) Non-naturally occurring nucleic acid compositions, their use for preparing formulations useful for transfecting nucleic acids into cells, and applications
CN1714094A (en) Cardiolipin compositions their methods of preparation and use
WO2024019770A1 (en) Methods of making ionizable lipids and lipid nanoparticles for mrna delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 167837

Country of ref document: IL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGE 1, DESCRIPTION, REPLACED BY A NEW PAGE 1

WWE Wipo information: entry into national phase

Ref document number: 2502285

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11105970

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2005501873

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1965/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003749443

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200500659

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038256428

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003749443

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003749443

Country of ref document: EP